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Abstract 
The protein oligosaccharyltransferase-48 (OST48/AGE-R1) is integral to protein N-glycosylation in 
the endoplasmic reticulum (ER) but is also postulated to act as a membrane localised clearance 
receptor for advanced glycation end-products (AGE). AGE accumulation is implicated in liver 
injury, diabetic kidney disease and diabetes-associated metabolic disorders. To date, however, there 
has been minimal investigation into the role of OST48 in kidney and liver function under either 
physiological or diabetic conditions. Here we have used both global (DDOST+/-) and targeted 
(podocyte specific; DDOST+/-Pod-Cre) knock-in mouse models to induce subtle increases in OST48. 
The burden of OST48 ligands, AGEs in these models, was modified by either dietary intervention 
or by the induction of diabetes to delineate the effects of increasing OST48 on the kidney and liver 
metabolome and proteome. Given previous studies, our postulate was that increasing OST48 would 
improve liver and kidney function in diabetes by facilitating removal of AGEs from the body. 
 
In the first study, we examined hepatic function and structure following global knock in of OST48 
in combination with a therapeutic reduction in dietary AGE intake. Global knock-in of OST48 
increased protein OST48 in the gastrointestinal tract, where it was highest in the duodenum. Both 
increasing gastrointestinal OST48 expression and/or greater consumption of AGEs modestly 
impaired liver function resulting in hepatic fibrosis. However, a combination of both high AGE 
dietary consumption and increased OST48 expression significantly exacerbated liver injury, but this 
was in the absence of steatosis. Interestingly, DDOST+/- mice had increased portal vein delivery 
and accumulation of hepatic AGEs which were associated with central adiposity, insulin secretory 
defects, shifting of fuel usage to fatty and keto-acids, and hepatic glycogen accumulation. These 
culminated in hepatomegaly along with hepatic ER and oxidative stress. This work is significant in 
that it revealed a novel role of the OST48 and AGE axis as a two-hit model of hepatic injury 
through ER stress, changes in fuel utilisation and impaired glucose tolerance. 
 
Our second and third studies aimed to delineate the physiological role of OST48 in the kidney 
through a global and podocyte-specific knock-in of OST48. Firstly, we investigated whether 
increased AGE excretion facilitated by modest increases in OST48, could prevent the development 
of diabetic kidney disease. This body of work is particularly significant, as to date there have been 
no studies examining whether elevating OST48 in diabetes is reno-protective, despite associative 
studies suggesting that a loss of OST48 is a pathological contributor to diabetes complications.  
 
Globally increasing OST48 did not protect against the development of experimental diabetic kidney 
disease. However, there appeared to be modest improvements in insulin secretion seen in both non-
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diabetic and diabetic DDOST+/- mice. This work is significant in that it revealed that globally 
elevating OST48 to facilitate AGE excretion does not protect against the development of diabetic 
kidney disease, contrary to perceptions in the current literature. 
 
Our third study used a more selective knock in of OST48 in an important kidney cell type, 
podocytes. Healthy podocytes, are critical for kidney health and function, and podocyte damage is 
postulated to be an early event in the development of diabetic kidney disease. We site-specifically 
increased podocyte expression of OST48 (DDOST+/-Pod-Cre). Despite facilitating greater clearance 
of AGEs into the urine, increasing podocyte OST48 concentration by 2.5-fold resulted in a decline 
in kidney function, even in the absence of diabetes. Specifically, serum creatinine was elevated 
which was exacerbated by diabetes and glomerular filtration rate was decreased. As expected, 
diabetes increased urinary albumin excretion, but this was not improved by increasing AGE 
clearance via podocyte OST48. Glomerular damage including mesangial matrix expansion was 
evident in all diabetic mice. Non-diabetic mice with podocyte specific over-expression of OST48 
also had significant glomerular damage including glomerulosclerosis, collagen IV deposition, 
basement membrane thickening and foot process effacement as compared with wild-type 
littermates. Tubulointerstitial fibrosis was also demonstrable in non-diabetic mice with increased 
podocyte OST48 expression and in all diabetic mice. Non-diabetic mice with increased podocyte 
OST48 had localized endoplasmic reticulum stress markers, evidenced by elevated sXBP1 and 
GRP78 expression, as seen in diabetic mice. Overall these studies suggest that facilitating AGE 
clearance by modestly increasing podocyte expression of OST48, results in endoplasmic reticulum 
stress and kidney dysfunction thereby worsening diabetic kidney disease. This work is of 
significance as it clarifies that therapeutic strategies which expose kidney tissues to greater AGE 
flux into the urine need to be better understood.  
 
Taken together, in this thesis, we present evidence that either global or podocyte-specific increases 
in OST48 expression do not protect against the development of experimental diabetic kidney 
disease. There may be yet undiscovered roles for this protein at this site. In addition, mice with 
global increases in OST48 had liver injury which were compounded by consumption of a high AGE 
diet. Hence, our studies indicate that efforts to increase the expression of OST-48 to improve 
pathology in these and other diseases, as well as to prevent aging may have undesirable side-effects 
leading to kidney dysfunction, liver fibrosis and glucose intolerance. 
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Chapter 1: General introduction  
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Diabetes, has two major forms, type 1 and type 2, both of which are characterised by uncontrolled 
hyperglycaemia, a predominant factor in the development of concomitant chronic complications. 
One major complication of key interest is diabetic kidney disease (DKD), which is a key 
contributing factor in diabetes related mortality and future risk of cardiovascular disease 1, 2. 
Therefore, understanding the pathophysiology of DKD is a focus for reducing the associated 
mortality in diabetes. Moreover, discovery of new pathological pathways is essential in identifying 
potential targets for therapeutics. In this thesis, the role of the AGE receptor 1 (OST48) as a novel 
contributor to DKD will be thoroughly described. Advanced glycation end-products (AGEs) are a 
heterogeneous and complex group of non-enzymatic, post-translational modifications on proteins.  
The formation of AGEs is accelerated by chronic hyperglycaemia and oxidative stress 3. The 
systemic reduction of AGEs using pharmacotherapies has been previously shown to improve kidney 
function 4 and AGE modifications on skin collagen are useful long term prognostic predictor of 
complications in individuals with type 1 diabetes5, as well as correlating with chronic kidney 
disease progression 6. Hence, the kidney is crucial in the detoxification of AGEs, through the 
filtration and active excretion into the urine 7, 8. Moreover, the receptor hypothesised to have a role 
in the clearance of AGE modified proteins from the circulation is OST48 9.  However, the specific 
nature of OST48 and AGE ligand binding is not well understood. Whether there is specificity to 
certain types of AGE adducts or preferential binding to large AGE multimeric complexes, much 
like RAGE, is currently unknown. Clearance of circulating AGEs is an exciting avenue of interest 
in the improvement of diabetic complications. 
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Chapter 2: Literature review 
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Introduction to this publication. This chapter consists of two peer-reviewed review article 
publications, the first was published in the Glycoconjugate Journal and focuses on the role of 
OST48/AGE-R1 in diabetic kidney disease.  
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Introduction. 
Currently, the world is faced with a rising pandemic of both type 1 (T1D) and type 2 (T2D) diabetes 
mellitus 10, 11, defined by persistent hyperglycaemia, which is an important factor in the 
development of concomitant complications 2, 12. A major complication, diabetic nephropathy (DN) 
is a global health concern and is an important risk factor of end-stage kidney disease (ESKD), and 
an independent risk factor of cardiovascular disease (CVD) 1, 2. Like all other forms of chronic 
kidney disease, patients with DN are most likely to die of premature CVD, than to survive to the 
point of ESKD. Understanding the pathophysiology of diabetic nephropathy is, therefore, a key 
challenge to reduce the burden of diabetes. The early clinical presentation of diabetic nephropathy 
is characterised by hyperfiltration, progressive proteinuria, and associative glomerular injury 
accompanied by tubulointerstitial fibrosis and, in the later stages, a steady progressive decline in 
renal function 13. Moreover, low estimated glomerular filtration rate (eGFR) and albuminuria are 
the two most potent known risk factors for CVD. Blood pressure lowering drugs such as 
angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) therapy 
are the only renoprotective interventions used clinically.  While, ACE inhibitors are often given as 
first line therapy, unfortunately, they are only partially effective, achieving approximately a 20% 
reduction in risk of future ESRD 14. Thus, there is an urgent need for interventions that will 
effectively delay or reverse CKD progression in patients with DN. Furthermore, despite the best 
available clinical management, involving both glycaemic 15, 16 and blood pressure control 17, 
including inhibitors of the renin-angiotensin-aldosterone system 18, 19, it is only possible to achieve 
at most a 30% improvement in declining diabetic kidney function. This is the principal reason why 
early detection and intervention are most important. Consequently even despite early intervention, 
end stage disease requiring a kidney transplant or dialysis develops in a considerable number of 
patients. In this review, we describe the role of AGEs and how a receptor, the AGE receptor 1 
(AGE-R1) provides a mechanistic and non-traditional aspect of DN. We also discuss the potential 
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targeting of AGE-R1 and whether this will improve or impair glomerular disorders and the process 
in understanding the clinical context of this receptor. 
 
Diabetic nephropathy. 
Although diabetes is predominately characterised as either T1D or T2D, the clinical distinction 
between kidney diseases in these two forms of diabetes is not easily defined. Rather, patient 
descriptions are often more complex and do not follow the linear trajectories often described as 
diabetic kidney disease. Risk of progression to end stage kidney disease is primarily predicted by 
low eGFR; previous rate of eGFR decline; and albuminuria. Indeed, other clinical factors add little 
to the predictive algorithm 20, 21.  However, early predictors of progressive DN are less clear.  
Interestingly, current reports from the United Kingdom, North America, and Australia suggest a 
gradual decline or plateau in ESKD incidence. However, this may simply be due to a combination 
of improved detection and intervention strategies, increased utilisation of non-dialysis supportive 
care (palliative care), and reversal of the trend for early-start dialysis in ESKD patients following 
the IDEAL trial 22, 23.  
 
Currently, there are no cell-specific therapeutics that target the underlying pathology in the kidney, 
as the specific roles of individual renal cell types in disease development are not well understood. 
However, given the complex cellular diversity and the various physiological roles of the kidney, it 
is difficult to pinpoint which functional aspects of the kidney are most affected by diabetes. Indeed, 
the kidney is a highly synthetic and secretory organ 24, 25 involved in the release of hormones, acute 
control of glycaemia through the modulation of gluconeogenesis and glucose reabsorption, as well 
as maintenance of fluid balance and blood pressure. Interestingly, it is thought that hyperglycaemia 
is the predominant mediator of pathology in resident kidney cells in diabetes through the specific 
induction of cellular events 26. However, this paradigm is also being challenged. 
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Early damage to the filtration units of the kidney, the glomeruli, is seen in DN, and the number of 
podocytes are drastically reduced in diabetic patients 27, 28. Podocytes are terminally-differentiated 
epithelial cells that, together with endothelial cells and the glomerular basement membrane, 
comprise the glomerular filtration barrier which functions as a barrier between the circulation and 
urinary filtrate. This filtration barrier selectively retains proteins in the bloodstream whilst freely 
filtering small molecules (such as glucose), into the urinary filtrate, the fate of which are determined 
through either reabsorption into the circulation, or excretion into the urine. Particularly in diabetes, 
podocytes are exposed to persistent long-term challenges, including glomerular hypertension 29, 
metabolic imbalances 30-32, and abnormal receptor stimulation 33, all of which are thought to 
contribute to the functional loss of podocytes, compromising the integrity of the filtration barrier. It 
is postulated that lost podocytes cannot be replaced by residual podocytes 34, and that residual 
podocytes are thought to be damaged by neighbouring damaged podocytes, in a cyclical manner 35. 
It is this decrease in podocyte density which mediates a progressive loss of nephrons (the filtration 
and reabsorption units of the kidney), and correlates with the degree of proteinuria (increased 
protein excretion in urine) over time 35. However, the pathological events that ultimately precipitate 
in nephron loss remain to be completely delineated. Progression of nephron loss and therefore 
kidney disease occurs in a stereotypical manner that generally initiates with podocyte injury, 
leading to tuft adhesion in the Bowmans capsule, and subsequent filtration of abnormal filtrate 
encroaching the glomerulotubular junction and degeneration of proximal tubules. Indeed, 
glomerular injury, more often than not, precedes tubulointerstitial damage in diabetes 36, although 
this paradigm is being increasingly challenged by more recent studies. Nevertheless, it is most 
likely that the additional changes in the tubulointerstitium and vasculature, in combination with 
early glomerular changes, are the major precipitating events in the pathology of DN. 
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Role of advanced glycation end-products in diabetic kidney disease. 
The kidney is most likely involved in the detoxification of AGEs through the filtration of 
circulating AGEs, and subsequently their active uptake and excretion 7, 8. AGEs are a heterogeneous 
and complex group of non-enzymatic, post-translational modifications on proteins, which begin 
with the covalent attachment of sugar moieties, which are described in other reviews in this issue. 
They can be both manufactured in the body, or absorbed from the dietary sources. Indeed, states of 
chronic hyperglycaemia and oxidative stress are known to accelerate the formation of AGEs 3. 
Consequently, AGE accumulation either through endogenous or exogenous sources 37, can have 
numerous detrimental effects that can be broadly characterised into three main pathways in the 
kidney. First, extracellular generation of AGEs have been implicated in modifications of matrix-
matrix, cell-cell, or matrix-cell interactions and under pathological conditions, excessive AGEs may 
lead to increased stiffening of the matrix 38, 39. Indeed the accumulation of AGE modifications on 
skin collagen is the best long term predictor of complications in individuals with T1D 5, as well as 
correlating with chronic kidney disease progression 6. Second, intracellular formation of AGEs can 
directly affect protein trafficking, protein function and protein turnover, and can contribute to 
intracellular reactive oxygen species (ROS) generation the third pathway by which AGEs may exert 
their pathological effect is via interactions with cellular receptors. Though there are a number of 
AGE receptors, the receptor hypothesised to have a role in the clearance of AGE modified proteins 
from the circulation is AGE-R1 9.  However, the specific nature of AGE-R1 and AGE ligand 
binding is not well understood. Whether there is specificity to certain types of AGE adducts or 
preferential binding to large AGE multimeric complexes, much like RAGE, is currently unknown. 
Clearance of circulating AGEs is an exciting avenue of interest in the improvement of diabetic 
complications. Reduced AGE absorption through the gut has been recently identified to improve 
glycaemic control in individuals with diabetes 40, which suggests that AGE clearance could be 
beneficial in the progression of diabetic nephropathy 41, 42. Therefore, understanding the role and 
function of AGE-R1 in the kidney in likely to provide insight into the pathogenesis of DN. 
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Furthermore, whether AGE excretion by the kidney is mediated by AGE-R1 expression is still not 
well defined, but may play an integral role in the development and progression of the chronic 
complications of the diabetic milieu. 
 
AGE-R1: a simple receptor with a complex function? 
AGE-R1, an evolutionarily conserved type 1 transmembrane protein 43, is encoded by the DDOST 
gene and has been postulated to function as a receptor for AGE turnover and clearance 44. Initially it 
was discovered that a p60 kDa sized protein could be involved in AGE binding and clearance. Upon 
further analysis it was identified that the plasma membrane component of this protein had a 95% 
similarity to that of OST-48 44, OST-48 is a 48kDa subunit that functions as part of the 
oligosaccharyltransferase complex, mediating the transfer of high-mannose oligosaccharides to 
asparagine residues within the lumen of the rough endoplasmic reticulum, a process known as N-
glycosylation 43. It was this N-terminal protein that was exposed on the plasma membrane as the 
p60 protein and was postulated to interact with AGEs 44, and function as a clearance receptor 44. 
Therefore, we believe that it is important to distinguish the difference between what is currently 
described interchangeably as OST-48 and AGE-R1. Specifically, while OST-48 may act as the 
active binding component of the AGE-R1 protein, OST-48 is also the key subunit in the 
oligosaccharyltransferase complex with disparate functions. This is an important distinction since 
although they are from the same gene, DDOST, OST-48 is not analogous to AGE-R1 and vice-
versa, but rather the AGE-R1 protein contains OST-48, and it is this “OST-48” N-terminal 
component of AGE-R1 that is postulated to bind to AGEs 44.  
 
AGE-R1 an alternative function in protein N-glycosylation. 
The homology between AGE-R1 and OST-48 becomes an important aspect to consider when 
targeting AGE-R1 expression in an attempt to decrease the AGE burden. Indeed, it is possible that 
secondary effects on oligosaccharyltransferase activity, and therefore the N-glycosylation pathway, 
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could occur following changes to AGE-R1. N-glycosylation of key kidney proteins has been 
previously shown to have an effect on kidney health and function. Notably, N-glycosylation is 
essential for the localisation of important kidney proteins such as nephrin, a podocyte-specific 
protein that mediates actin reorganisation under mechanical stress to assist with glomerular 
filtration 45. Mutations in nephrin, encoded by the NPHS1, are thought to be responsible for most 
reported cases of hereditary nephrotic syndrome 46.  Moreover, N-glycosylation has been identified 
as an essential modification necessary to retain proteins in the blood thereby preventing proteinuria 
through complex regulation of the actin cytoskeleton and downstream foot processes of podocytes 
47. Hence, it is important to discern which role of AGE-R1, whether its function as a proponent of 
N-glycosylation or its role as an AGE receptor, is more important to the development and 
progression of diabetic kidney disease, where both AGE accumulation and defects in N-
glycosylation play a central role in the pathogenesis.  
  
Interestingly, the AGE-R1 protein is present on most cells and tissues, including macrophages 48, 
mesangial cells 9, and mononuclear cells 49, and is also postulated to mediate the uptake and 
degradation of AGEs by the kidney 50. This process of AGE clearance by AGE-R1 is not well 
described and is thought to function primarily by sequestration and degradation of AGEs. 
Subsequently this process simultaneously results in a decrease in AGE accumulation, would likely 
decrease ROS generation thereby reducing AGE interaction and signalling with other AGE 
receptors (RAGE, galactin-3) or scavenger type receptors (SR-A, SR-BI and CD36). AGE-R1 is 
reported to be down-regulated by both, diets abundantly rich in AGE content 51, and by diabetes 50, 
52 in the kidney cortex.  These changes are associated with increased intracellular AGE 
accumulation and decreases in urinary AGEs 53. In addition, there are associations between lower 
AGE-R1 expression on circulating immune cells and a greater degree of kidney damage in a small 
cohort of patients with T1D 49.  However, there is some contradiction within the literature where 
T2D individuals with progressive diabetic nephropathy were reported to have an increased cell 
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surface and intracellular expression of AGE-R1 in their peripheral mononuclear cells 54.  It is 
therefore difficult to ascertain whether altered AGE-R1 expression in circulating immune cells is a 
direct or indirect result of diabetes. 
 
AGE-R1 an unusual receptor involved in diabetic nephropathy. 
Evidence linking AGE-R1 and diabetic nephropathy in clinical studies is sparse, where the only two 
studies that investigated this association have contradicting conclusions. A SNP array from the 
FinnDiane population study inferred that there was no association between SNPs of the AGE-R1 
gene, DDOST with nephropathy development in individuals with T1D 55. This contrasts a smaller 
study in T1D individuals which identified low levels of AGE-R1 mRNA in circulating mononuclear 
cells in conjunction with elevated levels of serum AGEs, in those individuals with nephropathy 49. It 
is worth noting however, that despite not reaching significance, the FinnDiane SNP array identified 
a trend towards an association between a SNP (rs2170336) in DDOST and DN in T1D 55.  
Therefore, this may be resolved by other longitudinal studies in DN and in the expansion of the 
sample size in future screens. In addition, the genomic profile does not directly translate into a 
corresponding proteomic profile. As such, these genome associative studies are not the most 
accurate indicator of the protein expression or function of AGE-R1 in the kidney, and further 
mechanistic work is required to better understand the role of AGE-R1 in the pathogenesis of DN. 
 
The mechanistic pathways of AGE-R1. 
Identifying the mechanistic function of AGE-R1 has proven difficult (Figure 1), since AGE-R1 
deletion is lethal in yeast 43, and embryonically lethal in mice and other organisms 56. This is likely 
attributable to impaired N-glycosylation.  Indeed, there is only one report of a living family with a 
mutation in DDOST where the children had a congenital disorder of glycosylation 57. This loss of 
function mutation in DDOST, did not result in diabetes or kidney disease, however, this is because 
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individuals with mutations in genes involved in glycosylation generally do not survive past 
childhood, due to systemic organ dysfunction 57, 58.  
 
Initially the biological functions of AGE-R1 were identified primarily through in vitro gene transfer 
and gene silencing studies 9, 59. Those studies suggested that decreases in AGE-R1 expression 
inhibited NADPH oxidases p47phox (also known as neutrophil cytosol factor 1) activity and 
gp91phox expression through suppression of Tyr311 and Tyr332 phosphorylation of protein kinase 
C-δ 60. Decreasing AGE-R1 altered the increased AGE-RAGE signal transduction via nuclear 
translocation of the p65 subunit of NFᴋB 61. Decreasing AGE-R1 expression in these studies also 
resulted in epidermal growth factor mediation of oxidative stress in a high AGE environment 51, 60. 
Furthermore, AGE-R1 inhibits AGE-induced Ser36 phosphorylation of the p66Shc isoform of 
SHC-transforming protein 1, a major oxidative stress and apoptosis-promoting adapter protein 59. 
This pathway may be of importance, since increased levels of p66Shc are linked with diabetes, 
atherosclerosis and kidney disease 62.  
 
Interestingly AGE-R1 has also been localised in astrocytes and retinal cells where binding studies 
identify that diabetes did not change the expression and/or the localisation of AGE-R1 63.  However, 
these studies confirmed that AGEs bind to AGE-R1 and are subsequently internalised Furthermore, 
there has only been a single in vivo investigation of untargeted AGE-R1 over-expression in 
transgenic mice, which demonstrated improvements in longevity, insulin sensitivity, and resistance 
to balloon injury in blood vessels 64.  However, this study investigated aged mice (>500 days old). 
To our knowledge, there are no studies which directly compare AGE-R1 modulation in young or 
adult mice, to investigate kidney function. More recently, another study has shown that AGE-R1 
may alter sirtuin-1 (SIRT1) activity. SIRT1 is similarly suppressed like AGE-R1 during diabetes, 
high fat feeding and aging 65-67. Furthermore, SIRT1 is thought to be integral in insulin signalling 
and secretion, insulin resistance, inflammation, and lifespan 65. Of note, Vlassara et al. suggests that 
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AGE-R1 overexpression blocks AGE-induced suppression of SIRT1 via NAD+/NADH, however 
this data has not yet been published, but was mentioned in a recent review 68. The pathway of AGE-
R1 activation and downstream effects on SIRT1 activity is of particular interest given that a recent 
study identified that SIRT1 overexpression in proximal tubule cells attenuated early glomerular 
disease in an experimental model of diabetes 69. Although the link between AGE-R1 and regulatory 
control of SIRT1 activity in podocytes and proximal tubule cells in the diabetic kidney remains to 
be defined, these studies underscore the potential importance of these two interdependent pathways 
in the diabetic kidney.  
 
Another consideration is the recent and accumulating evidence demonstrating that AGE modified 
proteins can modulate processes such as insulin secretion 70 and insulin sensitivity 71, 72, which 
could also influence the progression of diabetic kidney disease via changes in glucose and insulin 
handling. Hence, the story of increasing “protective” AGE-R1 expression during diabetic 
nephropathy may not be so straightforward, and AGE-R1 expression may reflect the current 
metabolic environment. Moreover, AGE-R1 has been shown to prevent AGE-induced impaired 
insulin signalling through the insulin receptor and insulin receptor substrate 1 (IRS1) in adipocytes 
both in vitro and in vivo 73, 74. Although this body of work was primarily investigated in vitro in 
cultured adipocytes, conclusions could be drawn that there are similar mechanisms at play in other 
insulin sensitive cells. One insulin sensitive cell of particular importance in diabetic nephropathy is 
the kidney podocyte. Without insulin receptor activity, the podocytes do not functionally develop 
and this impairs kidney function 30.  
 
Conclusions: AGE-R1 more than a clearance receptor? 
In this review we suggest that AGE-R1 is not just a clearance receptor for AGEs. Moreover, given 
the signal transduction pathways activated during AGE-AGE-R1 ligation, it is highly likely that it 
has an influential role in kidney function. Our understanding of how AGE-R1 functions in the 
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context of diabetic nephropathy is limited, since the focus has been largely on its function as a 
clearance receptor for AGEs.  Although this is feasible from a mechanistic perspective given the 
increased accumulation of AGEs seen in patients with diabetes, it largely ignores the important 
distinction that the component of AGE-R1 that is postulated to bind to AGEs is OST-48. Hence 
given the distinct role of OST-48 in N-glycosylation, it is very likely that these two distinct 
pathways of sugar chemistry may have some as yet undefined relationship as pathogenic mediators 
of nephropathy in diabetes. Further, increasing AGE-R1 levels in the kidney or in circulating 
lymphocytes following interventions has any beneficial effects in diabetic kidney disease remains to 
be elucidated by future studies. There are several important questions that remain to be answered 
specifically regarding the effect of AGE-R1 on kidney function and on kidney specific cells. 
Understanding the physiological effect of AGE-R1 in the diabetic milieu could provide us 
important information in further understanding and potentially developing AGE-R1 as a mechanism 
to counteract the burden of a high AGE environment. 
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Figure 1. Excessive AGEs impair insulin sensitivity in insulin-sensitive cells. In particular the 
podocytes in the kidney may be a key cell of interest. AGE mediated effects on the cell are 
controlled predominately through receptor interaction and AGE clearance is facilitated by AGE-R1. 
In a high AGE environment, prevalent in diabetic individuals, AGE-R1 expression is thought to be 
down-regulated by AGEs and therefore the protective effects of AGE-R1 receptor function through 
the upregulation of SIRT1 is thought to be impaired. Reduced AGE-R1 receptor could subsequently 
prevent the inhibition of AGE-induced Ser36 phosphorylation of p66Shc isoform of the SHC-
transforming protein 1 resulting in increased ROS. Furthermore, reduced AGE-R1 expression could 
subsequently affect protein post-translation modifications through impaired N-glycosylation of key 
podocyte proteins such as nephrin resulting in podocyte detachment from the GBM. Alternatively, 
exposure to AGEs reduces insulin receptor and IRS1 tyrosine phosphorylation and increases IRS1 
serine phosphorylation, resulting in impaired insulin signalling and decreased glucose uptake. This 
may have severe implications in an insulin sensitive cell such as the podocytes, leading to impaired 
metabolic activity, and consequently affecting podocyte function and health. Abbreviations: AGE, 
advanced glycation end productendproduct; AGE-R1, AGE receptor 1; FOXO, Forkhead box 
protein; FOXO3α, FOXO O3 α; IR, Insulin receptor; NADPH, nicotinamide adenine dinucleotide 
phosphate-oxidase; p66Shc, isoform p66 SHC-transforming protein; ROS, reactive oxygen species; 
SIRT1, NAD-dependent deacetylase sirtuin-1; SOD2, mitochondrial superoxide dismutase 2 [Mn]. 
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Introduction to this publication. The second review was published in Endocrinology and focuses 
on the role of ER stress in the pathophysiology of diabetic kidney disease. 
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Introduction. 
A tightly balanced homeostasis exists between the synthesis and degradation of proteins, which is 
maintained in the endoplasmic reticulum (ER). When imbalance occurs in either one or both of 
these facets, the ER activates coordinated adaptive responses known as the unfolded protein 
response (UPR) and the ER-associated degradation (ERAD) pathway in an attempt to restore 
balance in the ER. However, when these responses are saturated, the misfolded proteins accumulate 
in the ER, and cells develop a detrimental condition referred to as ER stress. The principles of the 
UPR are now relatively well defined 75-77, and the mechanisms of the signal transducers involved in 
the activation of this pathway have already been the subject of detailed reviews 75. However several 
key questions remain unanswered; (1) understanding how the UPR system integrates within specific 
resident cells of the kidney, (2) how diseases such as diabetes can promote an imbalance at these 
sites and (3) whether this ultimately leads to ER stress induced pathology culminating in 
nephropathy. This Review summarises recent developments in these areas and highlights new 
insights into translational applications into the clinical environment. 
 
Function of the endoplasmic reticulum. 
The ER functions as a site of synthesis, folding and maturation of secreted, luminal and 
transmembrane proteins. Synthesis of unfolded polypeptide chains occur in the rough ER where 
they undergo a maturation process, mediated by ER-resident enzymes and chaperones to form a 
stoichiometric stable conformation that is both energetically efficient and biologically activate 78, 79.  
 
During the synthesis of new proteins, the stoichiometry of the amino acid chains can potentially be 
altered by post-translational modifications, thereby profoundly affecting the energy signature and 
conformation of the folded protein. The role of post-translational modifications are becoming more 
apparent in the development of disease, particularly in chronic conditions such as diabetes 80, due to 
their impact on the generation of inappropriately folded proteins, seen most vividly in congenital 
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disorders of glycosylation 81. Subsequently the maturation of these nascent proteins are further 
dependent on the appropriate intracellular concentrations of calcium, glucose and adenosine-5’-
triphosphate (ATP), as well as the redox environment 82; all of which function as ER quality control 
factors. When proteins are both correctly folded and carry the appropriate post-translational 
modifications, the protein exits the ER and progresses through the secretory pathway to the Golgi 
body. When folded inappropriately, proteins accumulate within the ER, where UPR pathways are 
activated or terminally misfolded proteins are retro-translocated from the ER into the cytoplasm and 
undergo proteasome degradation in the ERAD pathway. 
 
Protein homeostasis within cells is particularly complex in nature as a balance is forged between 
constant turnover, the synthesis of new and the degradation of old proteins, as well as the influx of 
new proteins and precursors from the extracellular environment.  Unfortunately protein synthesis is 
inherently an error-prone process. Nevertheless, the dynamic nature of the ER allows cells to adjust 
their protein-folding capacity in response to fluctuations in the environment through transmembrane 
sensors that face the ER lumen and effectors that signal to other compartments of the cell, ensuring 
that secreted proteins are maintained at a high fidelity and at the correct concentrations to maintain 
protein homeostasis.  
 
Triggering the unfolded protein response (UPR). 
In mammalian cells, there are three major UPR pathways, activated by transmembrane sensors 
located in the ER membrane. These three major pathways depicted in Figure 1 are the inositol-
requiring protein 1 (IRE1), activating transcription factor-6 (ATF6) and the PKR-like ER kinase-
mediated (PERK) response. When protein synthesis and degradation in the ER is under homeostatic 
balance these three sensors are inactive and are hypothesised to be either; inherently inactive until 
unfolded proteins activate the sensors, maintained in an inactive state by the ER chaperone BiP, or a 
hybrid of both of these mechanisms 75. When activated, these pathways elicit several physiological 
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responses in order to counteract the increased accumulation of inappropriately folded proteins. 
Ultimately the purpose of the UPR pathway is to prevent an overabundance of misfolded proteins in 
the ER, which would consequently result in ER stress and potentially cell death. 
 
As misfolded proteins begin to accumulate in the ER, pathways of the UPR are activated. The first 
identified stress transducer IRE1 83, 84, undergoes oligomerisation following the accumulation of 
misfolded proteins and trans-autophosphorylates, which allosterically activates IRE1 
endoribonuclease activity via a conformational change 85. IRE1 mediated sequence-specific 
cleavage is targeted at X-box-binding protein 1 (XBP1) mRNA causing a frame shift in the coding 
sequence. A frame shift in XBP1 mRNA leads to the manufacture of the potent transcriptional 
activator (XBP1s), which activates genes encoding ER chaperones, enzymes that promote protein 
folding, maturation, secretion and ERAD components in an attempt to decrease ER load and relieve 
ER stress 86, 87. In parallel, ATF6 traffics to the Golgi in the presence of misfolded proteins where it 
is cleaved by proteases S1P and S2P 88 revealing a cytosolic fragment (ATF6n) which has a DNA 
binding domain. ATF6n subsequently migrates to the nucleus and in a similar manner to XBP1s, 
functions as a transcriptional activator for proteins which assist in resolution of ER stress by 
increasing ER capacity 89.  
 
Unlike the other two signal transducers, PERK phosphorylation activates a substrate known as 
eukaryotic translation initiation factor-2α (eIF2α). Activation of eIF2α reduces ER stress not by 
increasing the ER potential, rather eIF2α reduces the load on the load on the ER by inhibiting 
translation of new proteins from mRNA, leading to a reduction in overall protein synthesis through 
the inhibition of AUG codon recognition at the ribosomal level 90. 
 
The pathways of the UPR are essential in maintaining normal physiological functions, particularly 
in cells with a high rate of protein synthesis (kidney tubule cells 24, 25) or secretory function 
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(pancreatic β-cells and liver cells 91). Additionally since the UPR is conserved through many 
species, perhaps the design of this pathway was intended to be acutely beneficial dependent on the 
disease conditions, ameliorating damage. Unfortunately when the UPR is consistently activated 
such as in the presence of a chronic condition (such as diabetes) or during viral infection where 
cellular protein machinery is a means for viral replication, this adaptive response of the UPR system 
develops into a cytotoxic response promoting increased autophagy and apoptosis in an attempt to 
halt disease progression. 
 
ER stress in diabetes. 
The ER stress response is thought to be involved in several pathophysiological developments 
throughout the progression of diabetes and the associated chronic complications. The relationship 
between ER stress and the regulatory metabolic pathways in the ER are incredibly diverse. 
However as the current literature stands there appears to be a greater focus on ER stress and the 
downstream response in Type 2 diabetes (T2D) when compared to Type 1 diabetes (T1D), although 
this does not reflect the lack of relevance to this disorder as well as its role, in the development of 
complications associated with diabetes. 
 
ER stress in type 2 diabetes. 
Obesity is a common comorbidity in individuals with T2D characterised by a dysregulation in 
hepatic glucose production in combination with declining peripheral insulin sensitivity in the face 
of inadequate insulin secretion by the pancreatic β-cells. During the progression of T2D, there is an 
increased demand on the β-cells for insulin production in order to compensate for the ongoing 
intolerance. Moreover an unfortunate eventuality for the majority of obese type 2 diabetics is the 
advent of both glucotoxicity and lipotoxicity, where the imbalance between glucose and lipid 
homeostasis is a confounding result of nutrient excess as well as other comorbidities such as renal 
or hepatic disease. 
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Initial studies implicating ER stress in the pathogenesis of T2D identified that genetically obese 
mice (ob/ob) or mice fed a high fat diet inducing obesity had increased parameters of the UPR in 
the liver and adipose tissues 92. Similarly in insulin-resistant, non-diabetic humans there are marked 
increases in the presence of the IRE1 protein, an indicator of the adaptive response of the UPR 93. 
Despite only detecting changes in one arm of the UPR in the aforementioned study, another study 
cohort of severely obese patients whom underwent surgery assisted weight loss (BMI of 51.3 
compared to a BMI of 33.5) exhibited significant decreases in all aspects of the UPR arms in the 
majority of patients, suggesting a significant reduction of ER stress after gastric-bypass-induced 
weight loss 94. Noteworthy were the concomitant improvements in overall metabolic health afforded 
to these patients with the associative surgery. Evidently certain polymorphisms in the ATF6 gene 
were identified to be associated with T2D and modulation of plasma glucose in certain populations 
of the Dutch 95 and Pima Indians 96. Unfortunately amongst indigenous populations, specifically the 
Pima Indians 97, 98 and Australian Aborigines 99, 100, there is an inherent increased prevalence of 
diabetic comorbidities of both cardiovascular and renal disease. Whether genetic polymorphisms 
resulting in dysfunctional responses to ER stress could provide a basis accompanied by other factors 
for the accelerated progression of renal disease requires to be further established in these 
populations. These genetic associations are not constitutive amongst all ethnic backgrounds, with 
very little association noted amongst the certain population groups of the Chinese 101, 102, Caucasian 
101 and African-American 101 ethnicities. 
 
Prolonged exposure to nutrient excess in obese individuals promoting an environment of systemic 
ER stress could synergistically contribute to the pathophysiology of both insulin resistance and 
hyperglycaemia in obesity and T2D.  Each of these would clearly impact diabetic kidney disease 
where there are clear benefits of strict glycaemic 103, 104 and lipid control 105, 106, as well as weight 
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loss and caloric restriction 107, 108. However it is uncertain whether ER stress is a consequence of 
diabetes or the developed comorbidity of obesity. 
 
ER stress in type 1 diabetes. 
The traditional notion of T1D as primarily an autoimmune disease in humans is currently being 
challenged, and suggestively labelled as an inflammatory pancreatic-wide disease 109. Therefore this 
hypothesis raises interesting possibilities for other damage mechanisms such as ER stress as 
pathogenic mediators of T1D, given that islets isolated from individuals with T1D have increased 
levels of ER stress markers 110. A particularly interesting notion is the integral role of PERK, an ER 
stress signalling molecule in maintaining normal pancreatic health and function. Murine models 
with null mutations in Perk and mutations at the Ser51 phosphorylation site in eIF2α exhibit β-cell 
dysfunction and diabetes 111-113. Additional work has described the necessity for PERK function 
during the neonatal stage in pancreas development 114. Not only does PERK appear to be essential 
during the development of the pancreas, there is evidence that maintenance of normal β-cell 
function in the adult pancreas requires PERK 115. Furthermore, a mutation in the EIF2AK3 gene 
causes an autosomal recessive disease in humans known as Walcott-Rallison syndrome (WRS), 
whom often exhibit presentation of type 1 diabetes and renal insufficiencies during the neonatal 
period 116.  Interestingly, within the South Indian population, polymorphisms between the regions 
around the EIF2AK3 locus show an association with T1D susceptibility 117. Evidently when 
compared to the neighbouring regions, the Southern Indian population has the highest prevalence of 
kidney disease 118. It has also been observed that South Indian/Asian migrants have greater 
prevalence and faster progression of diabetic nephropathy when compared to their European 
counterparts 119, 120. This is particularly noteworthy as it may suggest that in the advent of ER stress 
a deficiency in PERK function could possibly play a contributing role in the progression of 
comorbidities, such as diabetic nephropathy. 
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ER stress and diabetic nephropathy. 
The role of ER stress in diabetic injury is not a new concept, with several indications that the 
presence of high glucose and free fatty acids in diabetic patients can induce ER stress. Implicating 
ER stress in the development of complications such as retinopathy 121, 122 and cardiovascular disease 
123, 124. However it has only been recently that there has been a focus on the potential role for ER 
stress in the pathogenesis of diabetic nephropathy (DN), with reports identifying the activity of the 
UPR in podocytes and other kidney cells 125-127.  Lindenmeyer and colleagues 128 identified the 
induction of UPR genes in humans with DN in a manner that is dependent on the degree of kidney 
injury. Where biopsies of patients with established DN exhibited increased levels of XBP1 and ER 
chaperones (HSPA5/GRP78, ORP150/HYOU1), when compared to those with only mild diabetes. 
Moreover, much like the pancreatic β-cells, the kidneys could constitutively be a site sensitised for 
the induction of ER stress, due to the high rates of protein synthesis. Although surprising, in 
humans it is estimated that the fractional rates of protein synthesis by the kidneys is approximately 
42% of the total body load daily 24 which is the highest in the body, further suggesting that kidney 
cells could be highly susceptible to ER stress, due to fluctuations in ER load. It is important to 
identify the disparate functions of the different resident kidney cells, and understanding how ER 
stress contributes to DN pathophysiology in the unique cell populations may elucidate novel 
pharmacological targets to remediate disease.  
 
ER stress mediate glomerular injury. 
Glomerular epithelial cells (podocytes) play an essential role in the health and function of the 
glomeruli. The podocytes are insulin sensitive cells 30, 129 that contract to limit diuresis, fluxing 
nutrients into the urine for the primary purpose of nutrient retention and post-prandial utilisation. 
Unfortunately the podocyte is a terminally differentiated cell with limited capabilities to regenerate 
and proliferate following injury, therefore reduced podocyte density is argued to be a crucial 
determinant in the development and progression of DN 130, 131. The induction of ER stress has been 
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elegantly reviewed in primary glomerular diseases 132. However developing a greater understanding 
as to how ER homeostasis is perturbed in these cells during diabetes and the subsequent adaptive 
responses is warranted. 
 
Mechanisms culminating in a stressed diabetic podocyte ER. 
Currently there are no direct studies investigating the specific role that ER stress plays through the 
targeted deletion of the ATF6/IRE1/PERK pathways in the podocytes, irrespective of diabetic 
conditions. Common insults such as the accumulation of advanced glycation end products (AGEs) 
and the activation of their receptors have been implicated in not only the pathogenesis of DN 133-136 
but also the induction of ER stress 126, 137. Moreover the accumulation of AGEs within the skin 
(representing tissue accumulation), also predicts those T1D individuals at greatest risk of 
developing nephropathy 138. Additionally albumin, a major component in the proteinuria observed 
in DN, is often reflective of progressive disease associated with a declining glomerular filtration 
barrier and increased leaching into the urine. Not only could excessive exposure of albumin to 
podocyte induce ER stress pathways leading to caspase-12 mediated podocyte apoptosis 
independent of mitochondrial input 139, it appears that the modification of albumin by AGEs 
enhances pro-apoptotic pathways in podocytes in a dose- and time-dependent manner 140. Moreover 
Chuang and colleagues 141 observed that both soluble and matrix bound AGEs induced apoptosis in 
podocytes in an additive manner and they further observed an increase in podocyte detachment 
when cultured in the presence of AGE-modified collagen IV. This is of particular interest as this 
may implicate not only the number of podocytes as a major determinant in the development and 
progression of DN but also their integrity, which has been well described 142. Moreover parallels 
can be drawn from this postulation, with the identification that the ability for the podocyte to 
effectively adhere to the extracellular matrix is a major determinant of ER stress induction and the 
subsequent development of glomerular injury 143. This may suggest that with the onset of podocyte 
dysfunction, ER stress could potentially exacerbate damage to the cell. 
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Moreover it is suggested that during the advent of hyperglycaemia in diabetic patients, the balance 
of the ER load in the podocyte is perturbed through a number of systemic pathways leading to the 
induction of ER stress and subsequently podocyte injury. Indeed, ER stress is induced in podocytes 
when acutely stimulated with both high 144 and low 47 glucose conditions, and it is apparent that 
there are regulatory mechanisms to alleviate this stress when podocytes are chronically exposed to 
hyperglycaemic conditions 137. Given that cell survival is promoted through the activation of 
autophagy in the advent of ER stress induced in mammalian cells under a high glucose environment 
145, it is likely that compensatory modifications to the ER could be directly linked with autophagy. 
 
Adaptive responses to a perturbed ER in the diabetic podocyte. 
Autophagy, a highly regulated lysosomal pathway, selectively targets and removes damaged 
organelles and is suspected to further function in tandem with the ER as a compensatory mechanism 
for proteosomal degradation 146. Not only is autophagy implicated to function in the adaptation of 
stress and survival mechanisms, autophagy may also play a distinctive role in the metabolic 
regulation of a cell. It appears that autophagy intricately regulates lipid metabolism 147, 148 and is 
involved in the degradation of large glycogen stores in the hepatocytes of neonates 149. Interestingly 
podocytes maintain a constitutively higher level of autophagy when compared to other intrinsic 
renal cells 150, 151.  This may simply be due to the limited capacity for regeneration of the podocyte 
and hence requirement to constantly recycle and renew cellular components. However there may be 
an underlying involvement of autophagy in the metabolic capacity of the podocyte. 
 
Recent developments in the understanding of the function of the protein kinase mammalian target of 
rapamycin complex 1 (mTORC1) in podocytes, has identified a relationship between autophagy and 
ER function. mTORC1 is a kinase complex involved in a myriad of cellular processes including a 
modulatory role of autophagy in response to nutrients such as glucose, amino acids and growth 
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factors 152. Interestingly, there is evidence to suggest that much like mTORC1, the UPR can be 
activated through various physiological stimuli (circulating FFAs 153, hypoxia 154 and growth 
stimuli 155, 156) that do not necessarily act through the accumulation of unfolded proteins in the ER. 
Moreover, a recent review 157 elegantly summarises how mTORC1 operates both upstream and 
downstream of ER stress signals, essentially inferring an intricate relationship between ER stress, 
autophagy and mTORC1. The speculation that mTORC1 may be involved in the pathogenesis of 
DN, came from the observation that an inhibitor of mTORC1 (rapamycin) attenuates renal 
hypertrophy in experimental models of DN 158. Rapamycin selectively restores integrity of the 
podocyte foot processes through the stabilisation of the protein nephrin to the filtration barrier and 
reduces subsequent tubular and glomerular damage 159, 160. Nephrin is an integral podocyte protein 
involved in the retention of larger macromolecules in the blood as well as playing a role in the 
membrane docking of the insulin sensitive glucose transporter, GLUT4 161. However, the changes to 
the role and function of mTORC1 in podocytes, in response to the metabolic alterations that occurs 
during diabetes remain to be completely delineated. 
 
It has been suggested however that mTORC1 activation in podocytes may play an essential role in 
the development of DN, as podocyte-specific mTORC1 activation in the absence of diabetes 
recapitulated several features of DN 160. Coupled with the chronic activation of mTORC1 in the 
podocytes, ER stress was enhanced in the glomeruli and the pathological changes in the podocyte 
could partially be attributed to ER stress 160. When mTORC1 activity was genetically reduced in 
diabetic mice, there was a significant reduction in the development of DN 160. Consistent with the 
ideology that the activation of the UPR can occur both downstream and upstream of mTORC1 
infers a particularly interesting notion, that in certain contexts, mTORC1 activation is a component 
in the process of ER stress induced cell toxicity, and if perturbed in the podocyte, could be a crucial 
to the development of DN. Indeed, despite the fact that hyper-activation of mTORC1 in mouse 
podocytes led to a phenotype akin to that of DN, reducing mTORC1 activity similarly promoted 
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podocyte dysfunction 162, suggesting that mTORC1 activity is essential for the development of the 
podocyte. Interestingly Inoki and colleagues identified that mTORC1 was causing podocyte 
dysfunction by retention of nephrin in the cytoplasm, where it could not localise to the renal 
filtration barrier during hyper-activation of mTORC1 in podocytes 160. Not only would impairments 
and the subsequent accumulation of dysfunctional nephrin promote ER stress 163, a decline in 
nephrin is known to lead to the development of proteinuria 164 and glucose homeostatic defects in 
podocytes. As alluded to above, a loss of nephrin also impairs GLUT4 trafficking to the plasma 
membrane and therefore insulin dependent glucose uptake 161. However the mechanism by which 
mTORC1 activity alters the capacity of nephrin to localise to the glomerular filtration barrier needs 
to be further explored. One possible avenue would be to identify the effects of post translational 
modifications of nephrin in the ER and golgi which could alter nephrin localisation and function. 
One particular modification of interest is N-glycosylation which plays a critical role in mediating 
membrane localisation of nephrin 45 and occurs within the ER. Hence, impaired protein 
modification in the ER, either through mechanisms directed or indirectly associated with ER stress, 
could also promote podocyte dysfunction and hence influence the progression of DN.  
 
These data illustrate a rather intricate relationship between ER stress and mTORC1 activity (Figure 
1). Although there is growing body of evidence indicating the crucial role for the mTORC1 
pathway in podocyte health, unfortunately as of current there is a limited understanding of the 
intersecting relationship between ER stress, mTOR and the UPR in the development of human DN. 
 
ER stress mediated tubulointerstitial injury. 
Tubulointerstitial damage is considered a final common pathway to end-stage kidney disease where 
the deposition of extracellular matrix, oedema and infiltrating cells separate the proximal tubules 
from their intimate contact with the renal tubular capillaries.  Since one of the primary functions of 
the proximal tubule is the reabsorption of molecules from the urinary filtrate such as glucose and 
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sodium and their return into the bloodstream, tubulointersitital fibrosis is the best prognostic 
indicator of progression to end stage renal disease requiring transplantation or dialysis.  However, in 
patients with diabetes, renal biopsies are no longer performed routinely due to an increased risk of 
bleeding and poor wound healing within this population. Proximal tubular epithelial cells (PTCs) 
are another particular cell of interest in the pathophysiology of kidney tubular injury in DN 165, 
particularly as they are highly susceptible to ER stressors 166 and are highly synthetic and 
metabolically active cells. 
 
Mechanisms culminating a stressed diabetic PTC ER. 
A common hallmark of DN is proteinuria, specifically the loss of albumin (albuminuria) and one of 
the central roles of the PTCs is the ability to reabsorb a proportion of proteins that may be filtered 
by the glomerulus and consequently end up within the urinary filtrate, which is exacerbated in the 
context of diabetes. Moreover several studies show a direct association between proteinuria and 
pathogenesis of tubular injury, with levels of albumin and modified-albumin as the determinant 
factor 167, 168. The effects of albumin on PTCs are biphasic, where on one hand albumin stimulates 
the growth of PTCs 169, 170 while on the other hand, excessive exposure to albumin is implicated in 
tubular atrophy in a pro-apoptotic and pro-inflammatory environment 171. Moreover albumin 
induced ER stress is implicated to cause tubular damage through the activation of caspase-12 
subsequently resulting in apoptosis of PTCs 171. Excessive reabsorption of albumin is also 
suggested to promote reactive oxygen species production and activation of PPARγ, stimulating 
GRP78 and eIF2α phosphorylation, both of which are markers of ER stress. ER stress subsequently 
stimulated downstream phosphorylation of JNK and NF-κB, resulting in increased expression of 
sodium dependent glucose transporter-2 (SGLT2) expression in cultured rabbit PTCs 172. Increased 
SGLT2 expression has previously been identified in PTCs isolated from the urine in T2D patients 
173. However mice which have the expression of SGLT2 ablated in the PTCs are not protected 
against the development or progression of kidney injury 174. Whether increased expression of 
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SGLT2 correlates with an increased risk for the development of DN is yet to be identified. 
Nevertheless, given the important role of SGLT2 in glucose reabsorption in the proximal tubule and 
the advent of new therapies in diabetic treatment regimens that target this protein to control 
hyperglycaemia by inducing glycosuria 175, 176, these pathways involving ER stress warrant further 
investigation and understanding. 
 
Adaptive responses to a perturbed ER in the diabetic PTC. 
What is particularly interesting to note is the identification of mTORC1 as an upstream mediator in 
PTCs, prior to the induction of ER stress as a result of excess albumin exposure 177, although 
whether albumin derived from human sera functions in a likewise manner is yet to be determined. 
Similar to podocytes, mTORC1 may also play a crucial role in the pathophysiology of kidney 
tubular injury through the regulation of ER stress. Interestingly it has been further elucidated in 
tubular cells that activation of pro-apoptotic pathways can be mediated by the induction of ER 
stress. Not only was mTORC1 identified to function downstream of ER stress in these cells, but 
subsequent mTORC1 activity involved pathways culminating in IRE1-JNK activation 159. 
Interestingly inhibition of mTORC1 with rapamycin under the same physiological conditions 
selectively inhibited the IRE1 pathway. This further implies mTORC1 activity both upstream and 
downstream of ER stress, however the reason that mTORC1 selectively activates the IRE1 branch 
and not the other branches of the UPR need to be further elucidated. One interpretation (Figure 2) 
suggests that albumin may direct ER stress in the proximal tubule of diabetic patients with 
albuminuria, mediating reduced insulin responsiveness in the PTCs through IRE-1JNK activation 
driven by mTORC1. Which the IRE1-JNK pathway has been shown to reduce insulin sensitivity in 
adipocytes, although mTOR activity was decreased in the adipose tissue of the T2D patients 178. 
Reduced mTOR activity could simply be a consequence of developed insulin resistance, as 
sustained activation of mTORC1 renders insulin receptor signalling pathways irresponsive to 
insulin 179. Ultimately whether mTORC1 activity would reduce insulin sensitivity in PTCs would 
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need to be confirmed. How insulin is relevant to the PTCs however is an evolving concept given 
that these cells are not physiologically insulin sensitive cells with respect to glucose uptake, nor do 
they manufacture the enzymes to perform glycolysis under normal conditions 180. A recent paper 
identified that indeed PTCs require insulin receptor mediated signalling for their normal function, 
and when the insulin receptor was specifically deleted in the PTCs, mice exhibited increased renal 
gluconeogenesis independent of glucose clearance, as well as enhanced insulin secretion and action 
181. It is postulated that the down regulation of insulin receptor and/or insulin-resistance in the PTCs 
could further contribute to hyperglycaemia, which could effectively enhance the risk for the 
development of DN. Although the mechanisms and actions of mTORC1 remain to be further 
explored in these cells, mTORC1 activity may play a central role not only in tubular injury via 
changes in insulin receptor signalling but also the development of DN. 
 
Therapeutic implications of ER stress modulators. 
Current approaches to treat DN largely target systemic blood pressure and/or intraglomerular 
hypertension. More often than not the first line of therapies for the treatment of DN are those which 
influence the renin-angiotensin system, including; angiotensin converting enzyme inhibitors 182 and 
angiotensin II (ANG II) receptor antagonists 18, with concurrent glycaemic control agents and often 
therapies for hyperlipidaemia. Despite these interventions, progression of DN to end stage renal 
disease can only be slowed but not cured. Although these interventions are currently the most 
effective clinical management of microvascular complications such as nephropathy, there is also 
evidence to suggest that strict glycaemic control does not necessarily reduce the risk of 
cardiovascular disease 183 and may potentially elevate the risk of a cardiovascular event 184. 
Moreover an unfortunate phenomenon often observed in the treatment of diabetes and its 
complications is poor adherence to treatment regimens, particularly with rates of adherence 
inversely proportional to the number of diabetic medications prescribed 185. Not only does this 
provide a rationale for the necessity of developing novel therapeutics which can target multiple 
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pathways, but also therapeutics that assists in improving patient compliance and as well as 
addressing other pathogenic mediators. A potential avenue to assist in achieving this therapeutic 
goal may be to target ER stress pathways. 
 
There are a myriad of compounds (Table 1) that improve ER folding capacity such as the chemical 
chaperones 4-phenylbutyric acid (PBA), taurine-conjugated ursodeoxycholic acid (TUDCA) and 
ER chaperones which reduce ER stress and improve insulin action and sensitivity 186, 187. Small-
molecule chemical chaperones such as TUDCA and 4-PBA are suspected to either enhance protein 
secretion or the folding capacity of the ER 188. Indeed, recent work in experimental models of DN 
show that 4-PBA 189 and TUDCA 140, 190 could potentially slow the progression of DN through the 
attenuation of ER stress induced apoptosis via the reduction of GRP78 and PERK expression, and 
the restoration of defective autophagy. However, it is not yet understood whether chemical 
chaperones could directly improve kidney function or these results are simply confounded by an 
improvement in glycaemic control seen with this class of agents. Despite a recent clinical 
investigation identifying that oral TUDCA administration can increase both hepatic and muscular 
insulin sensitivity in obese non-diabetic patients 191, markers of ER stress were not improved and 
therefore it is evident that there is still relatively little known on the long term efficacy and target 
specificity of these ER stress modulators in humans. 
 
Rapamycin (Sirolimus®) an mTOR inhibitor is currently approved by the FDA as an anti-restenosis 
agent and immunosuppressant. Clinical studies of rapamycin have shown significant efficacy in 
improving glycaemic control in T1D patients following pancreatic islet transplantation 192. 
Moreover Sirolimus-based trials of kidney transplantation also improved acute rejection and 
minimised nephrotoxicity often seen with other immunomodulators 193, 194. However it is difficult to 
determine if this class of agent or rapamycin-based therapeutics could be beneficial in the treatment 
of DN. Although mouse based experimental models suggest that a reduction in mTORC1 activity 
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could reduce the development of DN 160. Pharmacological inhibition of the mTOR pathway by 
rapamycin should be cautiously approached given the evident off-target effects described with 
longstanding application of rapamycin 195. 
 
Chemical chaperones that enhance protein folding are not the only avenue for ER modulation.  
Indeed, agents targeting other pathways such as dietary intervention through the reduction of 
palmitic acid could reduce ER stress mediated CHOP upregulation in podocytes and thereby 
attenuating pro-apoptotic pathways mediated by ER stress 196. Moreover antioxidant therapy using 
α-lipoic acid has been identified to reduce hepatic lipid accumulation, ER stress biomarkers and 
glomerular mesangial matrix expansion 197, 198 in other contexts. There is evidence that increasing 
consumption of polyunsaturated fatty acids (PUFAs) could attenuate DN both in animal models and 
in humans 199, although it remains to be determined whether this is modulated through an 
improvement in ER stability. These results suggest that perhaps dietary intervention involving a 
shift to increased unsaturated FFAs and reduced saturated fats could reduce ER stress-related renal 
cellular toxicity, particularly in T2D where lipid accumulation plays a more integral role in disease 
pathology.  
 
Concluding remarks. 
Whether ER stress directly contributes to the pathogenesis of nephropathy in the context of diabetes 
is still an unanswered question, but it is apparent that there is ER stress within specific renal cells.  
Furthermore there are certainly lessons to be learnt from other sites within the body, as it is evident 
that ER stress is not a uniform phenomenon particularly affecting highly synthetic sites. Hence 
drawing similarities between seemingly disparate sites which commonly present with ER stress in 
disease states may assist us to further understand this mystery. However, whether ER stress plays a 
causative role in the pathogenesis of DN is not yet defined, nor is the regulatory role of the UPR in 
highly synthetic organs such as the kidney, well understood. Certainly using modulators of ER 
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function and stress in experimental models of DN may provide some answers in this context. 
However the efficacy of these modulators to specifically target the renal cells of interest and there 
mechanism of action, needs to be further explored particularly given the complexity of the kidney 
which contains more than eight resident cell types. There should also be an emphasis placed on the 
investigation of societal and psychological implications as to how to best integrate these novel 
therapeutics in conjunction with proven treatment regimens to assist in improving government 
regulatory authorities, patient compliance and ultimately patient health and well-being. 
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Figure 1. A summary of the proposed mechanisms of ER stress induced podocyte dysfunction. 
(a) Glomerular stress events, in this case mediated by diabetes and the subsequent metabolic and 
catabolic changes perturb the balance between mTORC1, the ER and UPR. (b) AGE-BSA induces 
podocyte apoptosis mediated by caspase-12 activation 139, 140. (c) AGE-modified collagen IV 
contributes to podocyte detachment or dysfunction 141 and ER stress leading to the development of 
podocyte dysfunction. Obesity is likely a factor contributing to dysfunctional mTORC1 activity, 
given that mTORC1 activity is increased in the glomerular in obese db/db mice with a targeted 
genetic insertion of mTORC1 activity when compared to db/m mice 160. (d) Chronic changes in 
mTORC1 activity could be a determinant pathway leading to the development of diabetic 
nephropathy through various pathological changes to the podocyte 160, 161. 
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Figure 2. A summary of the proposed mechanisms of ER stress induced tubular dysfunction. 
Metabolic imbalances in diabetes (hyperglycaemia, inflammation and obesity) contribute to the 
interacting pathways of ER stress contributing to tubular dysfunction. Enhanced glycation is 
directly associated with pathways implicated in the development of diabetic nephropathy through 
the modification albumin generating large macromolecular complexes 135. (a) Excessive 
reabsorption of albumin is thought to overload the PTCs leading to ER stress-induced apoptosis 
mediated by caspase-12 activation 171. (b) Moreover albumin appears to have an intricate signaling 
pathway both upstream and downstream of ER stress mediated by mTORC1. Enhanced mTORC1 
activity in the PTCs not only contributes to pro-apoptotic pathways, but through the selective 
activation of the IRE1-JNK pathway could lead to decreased responsiveness to insulin in the PTC. 
(c) However it is important to note that the proposed pathway leading to IRE1-JNK induced insulin 
54 
 
resistance was only identified in adipocytes from T2D patients 178 and has not been substantiated in 
PTCs. (d) Furthermore JNK activation could further promote metabolic imbalances in the PTCs 
through ER stress induced NF-κB stimulation of SGLT2 expression 172. Understanding how ER 
stress might perturb the metabolic integrity of the proximal tubule could be a crucial pathway 
contributing to the pathogenesis of DN. 
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Table 1. ER stress modulators of particular interest 
ER stress modulator Mechanism of action Cell 
investigated 
Disease model Outcomes Reference 
4 Phenyl-butyric acid (4-
PBA) 
ER chaperone  STZ-induced 
diabetes 
Attenuates proteinuria, oxidative stress 
markers p-JNK, MCP-1 and TGF-β1, ER 
stress markers GRP78 and PERK 
189 
Taurine-conjugated 
ursodeoxycholic acid 
(TUDCA) 
ER chaperone Podocytes  Suppressed AGE-induced elevation of 
GRP78 and dose-dependently inhibited 
podocyte apoptosis 
140 
 ER chaperone  Clinical trial: 
obese non-
diabetic 
Increased hepatic and muscle insulin 
sensitivity. Markers of ER stress did not 
change 
191 
Palmitoleic/oleic acid Attenuated palmitic acid-
induced upregulation of 
CHOP 
Podocytes  Reduced palmitic acid-induced apoptosis of 
podocytes 
196 
Rapamycin Specific suppression of 
IRE1-JNK signalling 
PTCs TM-treated mice Suppressed renal tubular injury 159 
 Reversed mTORC1-
dependent podocyte 
injury 
Podocytes PcKOTsc1 mice Early intervention regenerated podocyte 
foot processes 
160 
Abbreviations previously not mentioned: STZ, streptozotocin; TM, tunicamycin; ATN, acute tubular necrosis; ACR, albumin:creatinine ratio
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Chapter 3: Increased liver AGEs 
induce hepatic injury mediated 
through an OST48 pathway. 
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Introduction to this publication. This chapter was published in Scientific Reports as an original 
article. In this report, we over-expressed the gene encoding for oligosaccharyltransferase-48 
(OST48), a protein of the N-glycosylation machinery. OST48 is also postulated to act as a 
membrane localised clearance receptor for advanced glycation end-products (AGE). In this novel 
study, over-expression of OST48 resulted in hepatic fibrosis, which proceeded without steatosis, 
obesity or a lack of physical activity.  
 
Specifically, we demonstrated the following; 1) Mice over-expressing OST48 (DDOST+/-) and 
wild-type mice exposed to AGEs had modest liver injury, but DDOST+/- mice exposed to AGEs 
had significant hepatic fibrosis and elevation in plasma concentrations of liver enzymes. 2) Fibrotic, 
dysfunctional livers demonstrated ER stress (SWATH proteomics) however there were no changes 
in N-glycosylation of secreted proteins. 3) DDOST+/- mice had increases in OST48 localisation to 
hepatic cell membranes and the small intestine which increased delivery and accumulation of 
hepatic AGEs ascertained by Near IR imaging studies. 4) DDOST+/- mice with hepatic fibrosis had 
specific increases in central adiposity but were not overweight (using EchoMRI and adipose tissue 
weight) and were more physically active (CLAMS). 5) Studies using OGTT and ITT showed 
impaired glucose tolerance and abnormalities in insulin secretion in DDOST+/- mice which 
exacerbated liver fibrosis. 6) Indirect calorimetry and hepatic SWATH proteomics/qPCR showed a 
shift towards fatty and keto acid utilisation in DDOST+/- mice which were more pronounced with 
AGE exposure. 7) High AGE fed DDOST+/- mice also had hepatic glycogen accumulation and 
hepatomegaly.  
 
In summary, in this group of studies we show a novel OST48/AGE pathway to liver fibrosis that 
progressed despite ample physical activity and in the absence of steatosis. The data also suggests a 
previously unappreciated physiological trafficking role of OST48 in the gastrointestinal tract and 
liver, which when dysregulated result in hepatic fibrosis. 
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Abstract 
The protein oligosaccharyltransferase-48 (OST48) is integral to protein N-glycosylation in the 
endoplasmic reticulum (ER) but is also postulated to act as a membrane localised clearance receptor 
for advanced glycation end-products (AGE). Hepatic ER stress and AGE accumulation are each 
implicated in liver injury. Hence the objective of this study was to increase the expression of 
OST48 and examine the effects on hepatic function and structure. Groups of 8 week old male mice 
(n=10-12/group) over-expressing the gene for OST48, dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase (DDOST+/-), were followed for 24 weeks, while randomised to diets either low 
or high in AGE content. By week 24 of the study, either increasing OST48 expression or 
consumption of high AGE diet impaired liver function and modestly increased hepatic fibrosis, but 
their combination significantly exacerbated liver injury in the absence of steatosis. DDOST+/- mice 
had increased both portal delivery and accumulation of hepatic AGEs leading to central adiposity, 
insulin secretory defects, shifted fuel usage to fatty and ketoacids, as well as hepatic glycogen 
accumulation causing hepatomegaly along with hepatic ER and oxidative stress. This study 
revealed a novel role of the OST48 and AGE axis in hepatic injury through ER stress, changes in 
fuel utilisation and glucose intolerance. 
 
Introduction 
Chronic liver disease is increasing globally as a result of obesity and diabetes, with non-alcoholic 
fatty liver disease (NAFLD), the most common liver disorder 200. However, NAFLD is 
asymptomatic and most individuals do not progress to non-alcoholic steatohepatitis (NASH). The 
development of NASH is postulated to be the result of a ‘second hit’ environmental factor 201.  
 
Glucose intolerance and dyslipidaemia which are often characteristic of NAFLD 202, facilitate the 
non-enzymatic post-translational modification of proteins, forming advanced glycation end products 
(AGEs) 203, which accumulate in tissues and contribute to liver fibrogenesis 203. Excessive exposure 
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to exogenous sources of AGEs, such as from food, can also exacerbate liver injury in the absence of 
glucose intolerance 204. This is likely via simple diffusion through the epithelium if cleaved 7, 
although AGE specific receptors may facilitate receptor-mediated gastro-intestinal trafficking. Once 
absorbed, AGEs are directed to the liver through the portal vein and excreted via the gall bladder by 
hepatic sinusoidal Kupffer and endothelial cells 205, and by renal clearance 206.  
 
The liver, however, is not only a site for the clearance of AGEs, but also a target organ and 
expresses various AGE receptors including the receptor for advanced glycation end-products 
(RAGE) 207, advanced glycation end product-receptor 1 (OST48 also known as AGE-R1) 44 and 
galectin-3 (AGE-R3) 208. There is accumulating evidence which suggests that in NAFLD, AGEs are 
a ‘second hit’ that triggers progression from steatosis to NASH 209. Galectin-3 (AGE-R3) has also 
been associated with inflammation and liver fibrosis 208 and a Phase 2a multi-centre trial is 
underway in individuals with portal hypertension and NASH cirrhosis (NCT02462967), using 
galectin-3 inhibitors.  Although the studies to date in galectin-3 have focused on its 
immunomodulatory roles, it is feasible that AGE binding and signalling via galectin-3 is also 
prevented by galectin-3 inhibition contributing to the efficacy of these agents in preventing liver 
pathology. 
 
The effects of AGEs are mediated by their receptors, which the effects can be broadly contrasting 
depending on the type of receptor. For example RAGE facilitates oxidative stress, cell growth and 
inflammation 210. Specifically, in chronic liver injury, hepatic expression of RAGE is significantly 
increased 211 and several studies in acute liver injury have identified that blockade of RAGE can 
ameliorate toxic, ischemic and cholestatic liver damage 212. Alternatively, another AGE receptor, 
OST48, is thought to be responsible for the detoxification and clearance of AGEs and negative 
regulation of AGE pro-inflammatory signalling 9, 49, and cellular oxidative stress 59. A decline in the 
expression of OST48 associated with increases in AGEs has been demonstrated both in murine 
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models 52 and in individuals with diabetes 49. Although OST48 is postulated as an AGE clearance 
receptor, its primary role is within the endoplasmic reticulum (ER) lumen 43 where as a subunit of 
the multiprotein oligosaccharyltransferase complex it facilitates enzymatic N-linked glycosylation 
of selected asparagine residues during protein translation 213. 
 
The present studies have demonstrated that OST48, a protein that was previously thought to 
mediate its effects via N-glycosylation or detoxification and clearance of AGEs, is rather a 
facilitator of increased AGE deposition in the liver. Specifically, a novel OST48-AGE pathway that 
leads to the onset of liver injury in combination with central adiposity and glucose intolerance, 
despite ample physical activity. These results establish a previously unappreciated physiological 
trafficking role of OST48 in the gastrointestinal tract and liver, which when dysregulated result in 
liver injury. 
 
Results 
Generation of a ubiquitous OST48 knock-in mouse model. OST48 knock-in mice 
(ROSA26tm1(DDOST)Jfo hereon termed as DDOST+/-) were heterozygous in their expression of human 
DDOST at the ROSA26 locus under the control of the ubiquitin promoter (Fig. S1A). There was a 
significant increase in hepatic OST48 gene (DDOST) expression (Fig. S1B), whilst endogenous 
gene expression (Ddost) was unaffected (Fig. S1C). Targeted proteomics identified that 32 week 
old DDOST +/- mice did not show a significant change in total OST48 protein in the gut using the 
major peptides detected (Fig. S1D). However, there is a substantial increase in OST48 protein in 
each major section of the gut than compared to an average of 5 differently tissue locations (Fig. 
S1D). Moreover, in fractionated liver tissue taken from DDOST+/- mice at the same time point, 
there was a significant increase in plasma membrane localisation of DDOST+/- fed on a high AGE 
diet (Fig. S1E). This increase in plasma membrane OST48 protein localisation and content in liver 
taken from DDOST+/- high AGE fed mice was not seen in the cytosol (data not shown). The small 
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intestine (duodenum, jejunum and ileum) had a high relative abundance of OST48 protein when 
compared with other tissues (Fig. S1D). 
 
In the absence of steatosis, hepatic injury was evident in DDOST+/- mice and this was 
exacerbated by a high AGE diet. Hepatomegaly was evident in DDOST+/- mice irrespective of 
the diet (Fig. 1A). H&E staining indicated that wild-type mice on a high AGE content diet had 
some hepatocellular ballooning, with modest rarefication of the cytoplasm (Fig. 1B). All 
DDOST+/- mice exhibited hepatocellular enlargement and ballooning, clusters of lobular plasma 
cells, increased inflammatory infiltration and an abundance of rarefied cytoplasm in hepatocytes 
(Fig. 1B), as well as increases in hepatic fibrosis exhibited by increased Sirius Red staining and 
positive α-SMA staining, respectively, (Fig. 1C & D). Although there was no substantial 
differences in Sirius Red staining between high AGE fed WT mice and DDOST+/- mice (Fig. 1C). 
We could however observe a gradual exacerbation of α-SMA staining in high AGE fed DDOST+/- 
mice (Fig. 1D). Plasma concentrations of the liver enzymes ALT and AST were also increased in 
DDOST+/- mice (Fig. 1E), and plasma ALP concentrations were the highest in DDOST+/- mice 
fed a high AGE diet, suggesting the presence of hepatocellular damage.  
 
Hepatocellular ballooning is often indicative of lipid droplet accumulation in the liver.  Despite the 
presence of vascular fibrosis, there were no differences among groups in hepatic Oil Red O staining 
for lipid droplets (Fig. 1F; right). Further, there was a significant reduction in both hepatic DAGs 
(Fig. 1F; top; P = 0.0101) and ceramides (Fig. 1F; bottom; P = 0.0246) associated with high AGE 
dietary intake. There was also a modest decrease (-30.9% low AGE diet and -15.9% high AGE diet, 
P = 0.0516, 2-way ANOVA) in hepatic ceramide content when comparing the DDOST+/- genotype 
with the WT mice however, this did not reach statistical significance. 
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DDOST+/- mice exhibited increased absorption of AGEs in the liver. The two-hit model of a 
high AGE diet and DDOST+/- mice exhibited increased deposition of both CML and OST48 in 
hepatic tissue sections (Fig. 2A). Oral administration of near-infrared labelled AGEs using 
IVIS/MR imaging, suggested prolonged exposure of AGEs in the liver of DDOST+/- mice (Fig. 
2B). We further identified that hepatic AGE deposition was greater in mice fed a high AGE diet and 
in DDOST+/- mice irrespective of dietary alterations (Fig. 2C). Although WT mice fed a high AGE 
diet had similar deposition of AGEs in the liver, it was identified that circulating AGE 
concentrations were reduced in all DDOST+/- mice as compared with high AGE fed littermate WT 
mice (Fig. 2D) indicating an increase in trafficking and exposure of AGEs from the circulation in 
the liver. 
 
Despite the absence of steatosis DDOST+/- mice had increased adiposity in addition to 
increased physical activity. There were no differences in body weight or lean body mass at either 
the beginning (Fig. S2A and B) or the end of the study (Fig. S2D and E) among mouse groups. 
Body fat mass was increased in DDOST+/- mice as compared to their respective WT group (Fig. 
3A; left), and this was more pronounced with high AGE feeding at the study end.  Indeed, 
adiposity, measured as the intra-abdominal fat pads (mesenteric and omental fat pads), was 
increased in DDOST+/- mice as compared to WT littermates (Fig. 3A; right). At the beginning of 
the study, there were no significant differences in adiposity between WT and DDOST+/- mice (Fig. 
S2C). Increased adiposity in DDOST+/- mice was not a consequence of reduced physical activity 
(Fig. 3B; left), nor of increased food intake (Fig. S2F). In fact, DDOST+/- mice exhibited 
increased locomotor activity during both dark/awake and light/sleep phases (Fig. 3C; right), 
irrespective of diet.  
 
Hepatic injury associates with ER stress, oxidative stress and activated inflammasome. 
Confocal microscopy, showed co-localisation of GRP-78 with OST48 (Fig. 4A). Unbiased 
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proteomic profiling of hepatic tissue using SWATH-MS, identified increases in key proteins 
involved in ER stress, specifically GRP78 (Fig. 4B; top) and EIF3A (Fig. 4B; bottom) in our two-
hit model of OST48 over-expression and high AGE feeding. The anti-oxidant enzymes 
SOD1/SODC (Fig. 4C; top) and SOD2/SODM (Fig. 4C; bottom) were increased in DDOST+/- 
mice irrespective of the diet consumed. DDOST+/- mice fed a low AGE diet also had increases in 
the redox responsive GPX1 (Fig. S3A; left) and aconitase/ACON (Fig. S3A; right) when 
compared to low AGE fed WT mice. Furthermore, we also observed a significant (P = 0.034) effect 
of a high AGE diet on increased 8-isoprostane levels in the urine (Fig. 4D). DDOST+/- mice fed a 
high AGE diet also had significant increases in the inflammatory proteins CD47 (Fig. S3B; left) 
and HA1D (Fig. S3B; right). 
 
Defects in N-glycosylation do not explain the hepatic injury seen in DDOST+/- mice fed on a 
high AGE diet. Prolonged ER stress culminating in liver injury is often associated with impaired 
ER function leading to changes in glycosylation occupancy on proteins. We therefore investigated 
whether DDOST+/- mice altered hepatic protein synthesis N-glycosylation. Fifty-six glycosylation 
sites were identified on mouse plasma proteins (Fig. S4A) with six indicating partial modification 
by N-glycosylation (Fig. S4B), but there were no differences among groups in glycosylation 
occupancy on plasma proteins (Fig. S4A), nor in plasma proteins specifically glycosylated and 
secreted by the liver (Fig. S4C).  
 
Hepatic injury was associated with changes in fatty acid metabolism.  
Using continuous indirect calorimetry, we determined that DDOST+/- mice had decreased 
respiratory exchange ratios during both the sleep/light (Fig. 5A; left) and active/dark (Fig. 5A; 
right) phases. This downward shift in RER suggested a proportional shift towards the use of free 
fatty acids and/or ketones for ATP generation as compared to wild-type littermates consuming 
either a low/high AGE diet. In support of this, an RER of 0.9, seen in DDOST+/- mice on a high 
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AGE diet during their active cycle, demonstrates a ~65:35 of carbohydrate:fat/ketone oxidation as 
compared with WT mice fed a low AGE diet, (RER of 0.98; ~93:7 carbohydrate:fat/ketone 
oxidation) 214. During the light cycle, DDOST+/- mice fed a high AGE diet had an RER of 0.88, 
demonstrating a large shift towards fatty acid and ketone oxidation (~59:41 carbohydrate:fat/ketone 
oxidation) as compared with low AGE fed WT mice (RER of 0.95; ~83:17 carbohydrate:fat/ketone 
oxidation). Moreover, we observed significant decreases in heat generation during both the 
sleep/light (Fig. 5B; left) and active/dark phases (Fig. 5B; right) specifically associated with a high 
AGE diet (P < 0.0001) in both WT and DDOST+/- mice.  
 
The gene expression of key enzymes involved in fatty acid utilisation by the liver were altered in 
DDOST+/- mice fed a high AGE diet (Fig. 5C). Specifically, there was a significant increase in 
Pparα gene expression in DDOST+/- mice fed a high AGE diet (Fig. 5C; top) as compared with 
other groups. The gene expression of Lepr (Fig. 5C; bottom) was decreased by both the high AGE 
diet and in all DDOST+/- mice. DDOST+/- high AGE fed mice, also showed a decrease in the gene 
expression of both Acadvl (Fig. S5; left) and Acadm (Fig. S5; right), encoding enzymes involved 
in the oxidation of medium and long chain fatty acids.  
 
Using SWATH-MS proteomics, significant increases in proteins associated with fatty acid 
oxidation, peroxisome proliferator-activated receptor (PPAR) protein signaling and fatty acid 
transport/export were demonstrated in DDOST+/- mice fed a high AGE diet when compared with 
WT low AGE fed mice (Fig. 5D). Specifically, the fatty acid oxidation enzymes ACOX1 and 
ACBP were increased, as well as the transport proteins FABP5 and FABPL, and the HDL core 
protein APOA1. The other proteins associated with lipid metabolism examined were not 
significantly altered.  
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DDOST+/- mice exhibit impaired glucose tolerance at a young age. Young (8 week old) 
DDOST+/- mice had increases in fasted blood glucose concentrations (Table 1 and Fig. S6A), 
lower fasting insulin concentrations and decreases in first phase insulin secretion (Table 1 and Fig. 
S6B) during ipGTT as compared with WT littermates. There were no differences in fed blood 
glucose concentrations (Table 1), or in insulin tolerance tests (Fig. S6C) among young mice.  
 
Adult DDOST+/- mice exhibited glucose intolerance which is augmented by high AGE dietary 
intake. By the end of the study, all DDOST+/- mice had elevated glycated haemoglobin (Fig. 6A) 
and lower fasted plasma insulin concentrations (Fig. 6B), without differences in fasted or fed 
plasma glucose concentrations as compared with WT mice (Table 1).  However, high AGE fed 
DDOST+/- mice also had increased 2 hour plasma glucose concentrations following a 2 g/kg 
glucose bolus (ipGTT), as compared with other groups (Fig. S7A and B).  While on a high AGE 
diet, WT mice were less glucose tolerant as compared with low AGE fed mice (Fig. S7C).  
 
In response to an insulin bolus (ipITT), DDOST+/- mice fed a high AGE diet had higher plasma 
glucose concentrations than other groups (Fig. 6C).  Fasting plasma glucagon concentrations were 
not increased (Table 1), but hepatic glycogen storage was increased by 30-40% in DDOST+/- mice 
(Fig. 6D). When compared with the WT low AGE fed group, all mice also had lower protein 
intensities of 1,4-alpha-glucan-branching enzyme (GLGB), a facilitator of glycogenolysis (Fig. 6E), 
consistent with greater levels of liver glycogen described above.   
 
The gene expression of the gluconeogenic enzyme, pyruvate carboxylase kinase (Pck2; Fig. 6F) 
was increased by high AGE dietary feeding. Pathway analysis of proteins involved in GNG showed 
that hepatic proteins involved in oxidative phosphorylation were elevated in all mouse groups when 
compared with WT low AGE fed mice (Fig. 6G). 
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DDOST+/- mice on a high AGE diet exhibit increased amino acid metabolism.  
Increased gluconeogenesis and hepatic glucose release to potentially sustain an associated increased 
physical activity can be further substantiated by the evident increased circulating concentrations of 
the amino acids alanine (Fig. 7A) and serine (Fig. 7B) and the loss of glucogenic glycine in 
DDOST+/- mice (Fig. 7A). Plasma concentrations of the essential amino acids lysine and histidine 
(Fig. 7C) were also increased in DDOST+/- mice. Plasma concentrations of both tyrosine and 
tryptophan were also increased in the high AGE fed DDOST+/- mice when compared with other 
mouse groups (Fig. 7D). Pathway analyses showed an increase in protein associated with amino 
acid metabolism in high AGE fed DDOST+/- mice (Fig. 7E). There were no other changes 
observed in circulating concentration of other amino acids (Fig. S8).  
 
Discussion 
Our discovery of the accumulation of AGEs in the liver through an OST48 mediated pathway of 
uptake and clearance is novel. Despite the unconventional pathway of liver injury (normally the 
presence of steatosis leading to the onset of fibrosis) in our DDOST+/- mice, this allowed us to 
identify other metabolic factors that may contribute an important role in the development of liver 
injury 215. A recent study in children with NAFLD demonstrated that the presence of early portal 
inflammation on biopsy was independently associated with severity of liver fibrosis and metabolic 
risk factors for type 2 diabetes, in particular waist circumference 216. Indeed in that study, central 
adiposity was the only non-invasive variable associated with biopsy proven portal inflammation. 
These findings are consistent with the present study, where central adiposity was seen in concert 
with early liver injury and portal fibrosis in DDOST+/- mice fed a high AGE diet. Whether 
DDOST+/- mice bypass the development of steatosis and proceed directly into fibrogenic pathways 
would require further investigation into a high fat diet model. Despite this caveat what was 
particularly interesting was that central adiposity and liver injury persisted in DDOST+/- mice fed a 
high AGE diet, despite them partaking in greater levels of physical activity. This interesting finding 
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reiterates the complexity of the relationship between metabolic factors and liver injury, given that 
exercise is a feasible intervention to improve liver fibrosis in patients with NAFLD 217 and relates to 
adiposity in NAFLD 218. 
 
The liver is a node which controls systemic glucose and lipid fluxes in the body, balancing these 
against its own energy requirements 219. These processes are influenced heavily by pancreatic islet 
function via the endocrine hormones insulin and glucagon 220 as well as other hormones. In the 
present study, abnormalities in insulin secretion and elevations in glycated haemoglobin were seen 
in the context of hepatic injury and increased fuel oxidation, particularly of fatty acids in high AGE 
fed DDOST+/- mice. This is in agreement with previous evidence that a shift in hepatic fuel 
utilisation towards fatty acids results in liver damage 221. The increased utilisation of fatty acids for 
-oxidation, and likely increased fatty acid export/transport proteins, may also explain the lack of 
hepatic fat accumulation seen in DDOST+/- mice fed a high AGE diet. Surprisingly, this led to an 
increase in central adiposity, despite increased physical activity and the absence of changes in 
caloric intake and lean body mass. There also appeared to be an excess supply of circulating 
glucose generated from hepatic gluconeogenesis which may be required by the skeletal muscle to 
facilitate the increases in physical activity seen in DDOST+/- mice, rather than for thermogenesis. 
This is also supported by the decreases in heat generation seen in AGE-R1 mice fed a high AGE 
diet. A futile cycle of energy generation in adipocytes has been linked to reduced body fat storage 
222, however it has not been previously linked to the development of liver fibrosis. 
 
In summary, this group of studies revealed a previously unappreciated role of the OST48-AGE axis 
within the body. Indeed, the data suggest that the “trafficking role” of OST48 in normal hepatic 
physiology is not solely involved in protein N-glycosylation or elimination 
(detoxification/clearance) of AGEs but could also alter gastrointestinal uptake through the small 
intestine of AGEs leading to changes in glucose homeostasis, hepatic function and fuel utilisation.  
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The physiological significance of this should form the basis of future studies. In the context of a 
high AGE diet, increases in OST48 expression exacerbated liver injury leading to fibrosis, likely via 
known pathways of injury including oxidative and ER stress. Further studies into the role of hepatic 
and gastrointestinal OST48 mediated AGE uptake could lead to a novel approach to minimise liver 
injury. 
 
Materials and Methods 
Animal Model. C57BL/6J mice (The Jackson Laboratory, United States) were genetically modified 
via the Cre-loxP recombination system (Ozgene, WA, Australia) and ubiquitous genetic knock-in of 
the human gene encoding OST48 (DDOST) at the ROSA26 locus with removal of the delivery 
neomycin cassette, as described in Supporting Experimental Procedure 1 and Supporting Fig. 1. 
DDOSTflox/flox mice are referred to as the wild-type (WT) background and DDOSTflox•Cre/flox are 
labelled as the genetic OST48 heterozygous knock-in mouse model (DDOST+/-). Eight week old 
male DDOST+/- mice and littermate controls (WT) were randomised to be fed either AIN-93G 
(low AGE diet; Specialty Feeds, Perth, Australia) 223 or baked AIN-93G (1 hour at 1000C; high 
AGE diet), which contained a 5-fold higher content of the AGEs, N(ε)-(carboxymethyl)lysine 
(CML), N(ε)-(carboxyethyl)lysine and methylglyoxal 72 for 24 weeks. Heat labile vitamin contents 
(vitamin A and thiamine) were not decreased by the heating protocol 72. Mice were allowed access 
to food and water ad libitum and were maintained on a 12 hour light:dark cycle at 220C. All mouse 
experiments were performed following approval from the AMREP Animal Ethics Committee and 
as per guidelines from the National Health and Medical Research Council of Australia. 
 
Plasma AGE measurement. CML concentrations in plasma were measured by an in-house indirect 
ELISA as previously described 50.  
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Human and mouse OST48 ELISAs. Mouse and human OST48 concentrations were determined in 
hepatic cortical membrane and cytosolic fractions by commercial sandwich ELISAs (Cloud-Clone 
Corp., Houston, United States), according to the manufacturer’s specifications. 
 
Liquid Chromatography-Mass Spectrometry (LC-MS/MS). As previously described 224, 
proteins were extracted from whole liver tissue samples using guanidine denaturing buffer (6 M 
guanidinium, 10 mM DTT and 50 mM Tris-HCl). Reduced cysteines were alkylated with 
acrylamide, and quenched with excess DTT. Proteins were precipitated in 4 volumes of 1:1 
methanol:acetone and digested with trypsin. Peptides were desalted and analysed by Information 
Dependent Acquisition LC-MS/MS as described 225 using a Prominence nanoLC system 
(Shimadzu, NSW, Australia) and Triple TOF 5600 mass spectrometer with a Nanospray III 
interface (SCIEX). SWATH-MS analysis was performed 226 and analysed with MSstats as 
previously described. Differentially abundant proteins were analysed using DAVID 227. 
 
Histology and Immunofluorescence. Haemotoxylin and Eosin, Masson’s Trichrome and Sirius 
Red (Sigma-Aldrich, United States) stains were completed on 10% Buffered formalin fixed paraffin 
sections. Collagen content of the liver was quantified histologically using computerised 
quantification of picrosirius red staining, as described previously 212. Oil-Red-O (Sigma-Aldrich, 
USA) staining was performed on frozen OCT embedded cryosections as previously described 228. 
All sections were visualized on a slide scanner (Virtual Slide System VS120, Olympus, Tokyo, 
Japan) and viewed in the supplied program (OlyVIA Build 10555, Olympus, Tokyo, Japan). 
Briefly, for immunofluorescence staining, 4% PFA fixed frozen  liver sections were  dual stained 
with both anti-CML (1:125 dilution; ab30917; Abcam, United Kingdom) and OST48 (1:100 
dilution; sc25558; Santa Cruz biotechnologies, United States).  Dual staining on paraffin buffered 
formalin fixed sections was with GRP78 (1:50 dilution; sc1050; Santa Cruz biotechnologies, United 
States) and OST-48 (1:100 dilution; sc74407; Santa Cruz biotechnologies, United States). 
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Serum and urine biochemistry and analysis of hepatic lipids. The plasma concentrations of 
alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) were 
measured by an auto-analyzer (Beckman Instruments, USA). Hepatic diacylglycerols (DAGs) and 
ceramides were extracted and quantified by thin layer chromatography and a liquid scintillation 
analyzer (LS6500; Beckmann Coulter Inc., CA, USA) as previously described 229. Lipid 
peroxidation was examined by urinary 8-isoprostane in a competitive ELISA (Oxford Biomedical 
Research, United States), according to the manufacturer’s specifications. 
 
Glucose and insulin tolerance tests. Intraperitoneal glucose tolerance tests (ipGTT) were 
performed following a 2 g/kg D-glucose bolus as previously described 230. Insulin was determined 
by rat/mouse insulin ELISA (RnD systems, MN, United States). Intraperitoneal insulin tolerance 
test (ipITT), to determine glucose output was performed using a 1 IU/kg bolus of Humulog fast-
acting insulin (Eli Lilly, IN, United States). Area under the curve was calculated using the 
trapezoidal rule (GraphPad Software, CA, United States).   
 
Indirect calorimetry and assessment of body composition. Whole body composition was 
measured at 32-weeks of age in conscious, but physically restrained mice using an EchoMRI™ 3-
in-1 body composition analyzer (EchoMRI, TX, USA). A cohort of mice were allocated for 
repeated measures of energy expenditure by indirect calorimetry (VO2, VCO2) normalised to lean 
body mass, locomotor/physical activity and rate of energy expenditure (heat generation) using a 
Comprehensive Lab Animal Monitoring System (CLAMS; Columbus Instruments, OH, United 
States). Data was collected over a 24-hour cycle period, post-acclimatisation to the cages for a 12-
hour period.  
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Liver glycogen content. As previously described 231, total liver glycogen content was determined 
using a glucose oxidase/peroxidase assay procedure and absorbance was analysed on a UV-1700 
PharmaSpec UV-vis spectrophotometer (Shimadzu, NSW, Australia). 
 
Quantitative real-time PCR. Messenger RNA was purified and was used (1 µg) to synthesize 
cDNA using SuperScript first-strand synthesis system (Invitrogen). Quantitative real-time PCR was 
performed using pre-designed TaqMan Gene Expression Assays® for Acadm, Acadvl, Acox1, 
ADRB2, Ccl2, Col1a1, Col3a1, Ddost, DDOST, G6pc, Gcgr, Got1, Gyk, Kcnma1, Lepr, Pck1, 
Pck2, Ppara, Slc27a4 and Slc37a4 (Supporting Experimental Procedure 2; Life Technologies, 
Mulgrave, VIC, Australia) in ViiA™ 7 real-time PCR system (Applied Biosystem, Darmstadt, 
Germany). Gene expression levels were calculated after normalisation to an endogenous 
multiplexed control (18S) using the ΔΔCT method as previously described 72 and expressed as 
relative fold change compared to the wild-type mice fed a high AGE content diet. The results are 
represented as mean ± %CV.  
 
Amino acid measurements. Approximately 40 µl of serum was mixed with 160 µl of an extraction 
solution (3:1 ratio of analytical grade methanol to ddH2O), centrifuged at 16,000 × g for 10 minutes 
and the supernatant removed for processing. Amino acids were measured by HPLC as described in 
Chacko et al. 232.  
Statistical analysis. Results are expressed as mean ± SD (standard deviation), and analyzed by 2-
way ANOVA followed by post hoc testing for multiple comparisons using the Bonferroni method 
unless otherwise specified. α (genotype effect) P < 0.05, β (diet effect) P < 0.05, δ (interaction 
effect) P < 0.05 were reported. For comparison between groups as required, a two-tailed unpaired 
Student’s t-test was used. For SWATH-MS, MSstatsV3.5.1 was used to detect differentially 
abundant proteins estimating the log-fold changes between compared conditions of the chosen 
73 
 
experimental group and with the WT mice fed a low AGE diet group. For all calculations a P < 0.05 
was considered as statistically significant. 
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Figures and Figure Legends 
 
Figure 1. A diet high in AGE content is a promoter of portal vein fibrosis following up-
regulation of DDOST+/- in the absence of steatosis. (A) Cull liver weight. (B) Representative H 
& E stained paraffin-embedded liver tissue sections. (C) Hepatic fibrillar collagen quantification of 
Sirius Red stained images (left).  Representative images of fibrosis stained images of Sirius Red 
localised around fibrillar fibrosis extending between hepatocytes (right). (D) Hepatic α-SMA 
positive quantification of immunofluorescent stained images (left). Representative images of α-
SMA positive staining extending between hepatocytes (right). (E) Liver function tests for ALT 
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(left), AST (middle) and ALP (right). (F) Hepatic diacylglyceride (top) and ceramide (bottom) 
accumulation. Representative images of Oil Red O staining for lipid droplets in liver tissue (right). 
Data represented as means ± SD (n = 4-9/group). *P < 0.05, student’s t-test. Genotype effect P < 
0.05, (diet effect) P < 0.05, 2-way ANOVA and multiple comparison of genotype, diet and 
interaction by Bonferroni’s post hoc test. Representative images scale bar = 50µm (outside box) 
and 20µm (inside box). 
 
 
Figure 2. DDOST+/- mice have increased hepatic uptake of AGEs. Wild-type and DDOST+/- 
mice were fed either a high AGE (baked AIN-93G diet) or a low AGE (unbaked AIN-93G) diet for 
24 weeks. (A) Immunofluorescence for OST48 (red) and the AGE, CML (green) in OCT liver 
sections. Representative images; scale bar = 20µm (B) Near-infrared imaging of AGE uptake in the 
liver following oral gavage using IVIS/MRI. (C) AGE concentrations in hepatic tissue by 
immunofluorescence quantification. (D) Plasma AGE concentrations by ELISA. Data represented 
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as means ± SD (n = 4-9/group). Genotype effect P < 0.05, 2-way ANOVA and multiple comparison 
of genotype, diet and interaction by Bonferroni’s post hoc test. 
 
 
Figure 3.  DDOST+/- mice have increased central adiposity despite greater physical activity.  
(A) Fat percentage measured by EchoMRI (left) and weight of omental fat deposits (right). (B-C) 
CLAMS apparatus measured 24 hour physical activity and caloric intake at 24 weeks post-dietary 
intervention in WT (●) and DDOST+/- (●) mice fed on either a high AGE diet (closed circles) or a 
low AGE diet (open circles). (B) Total locomotor activity in the horizontal plane measured by 
infrared beam breaks. (C) The line graphs show average hourly heat generation over the 24-hour 
period. The bar graphs on the right show the average physical activity over the entire 12-hour 
light/sleep (left) and dark/active (right) period. Data represented as means ± SD (n = 4-9/group). 
*P < 0.05, student’s t-test, α (genotype effect) P < 0.05, β (diet effect) P < 0.05, as per figure above. 
2-way ANOVA and multiple comparison of genotype, diet and interaction by Bonferroni’s post hoc 
test. 
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Figure 4. A high AGE diet promotes liver fibrosis and correlates with increased ER stress 
markers following increases in DDOST+/- mice.  (A) Immunofluorescence for OST48 (red), the 
ER stress marker GRP-78 (green) on paraffin liver sections (hepatocytes). (B) SWATH-MS protein 
intensities of ER stress pathway related proteins. GRP78 (top) and EIF3A (bottom). (C) SWATH-
MS protein intensities of oxidative stress pathway related proteins. SODC (top) and SODM 
(bottom).  (D) ELISA identifying content of urinary 8-isoprostane. Data represented as means ± SD 
(n = 4-9/group). *P < 0.05, MSstatsV3.5.1 determined significant log fold changes in the protein 
intensities between the selected experimental group and the WT low AGE diet group. 
Representative images scale bar = 20µm. 
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Figure 5. DDOST+/- mice have a shift towards increased fatty acid utilization. (A) CLAMS 
apparatus measured respiratory exchange rate at 24 weeks post-diet modification. Average 
difference in respiratory quotient corrected to lean body mass measured by indirect calorimetry 
during the entire 12-hour light/sleep (left) and dark/active (right) period. (B) Average difference in 
heat production measured by indirect calorimetry during the entire 12-hour light/sleep (left) and 
dark/active (right) period. (C) Real-time PCR of liver tissue targeting genes of interest Pparα (top) 
and Lepr (bottom) (n = 4-8 per group in triplicate). (D) Heat map representation of SWATH-MS 
proteomics data for enzymatic pathways involved in fatty acid oxidation. Significant proteins are 
represented as the Log2 fold change where red indicates a decreased and blue indicates an increase 
in protein concentrations. Data represented as means ± SD (n = 4-9/group). For proteomics, 
MSstatsV3.5.1 determined significant (P < 0.05) log fold changes in the protein intensities between 
the selected experimental group and the WT low AGE diet group. *P < 0.05, student’s t-test. 
Genotype effect P < 0.05, (diet effect) P < 0.05, 2-way ANOVA and multiple comparison of 
genotype, diet and interaction by Bonferroni’s post hoc test. 
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Figure 6. Hepatic fibrosis associated with glucose intolerance, increased glucose synthesis and 
storage in high AGE fed DDOST+/- mice. (A) Glycated haemoglobin. (B) Fasting plasma insulin 
concentrations. (C) Plasma glucose curve over 120 mins following a 1IU/kg insulin bolus (ipITT) 
and area-under-the-curve (AUC) analysis. (D) Hepatic glycogen measured in liver tissue. (E) 
SWATH-MS protein intensities for the glycogen storage pathway protein (GLGB). (F) qPCR of 
Pck2, the enzyme involved in gluconeogenesis. (G) Heat map representation of SWATH-MS 
proteomics data for enzymatic pathways involved in GNG. Significant proteins are represented as 
the Log2 fold change where red indicates a decreased and blue indicates an increase in protein 
concentrations. Data represented as means ± SD (n = 4-9/group). For proteomics, MSstatsV3.5.1 
determined significant (P < 0.05) log fold changes in the protein intensities between the selected 
experimental group the WT low AGE diet group. *P < 0.05, student’s t-test. Genotype effect P < 
0.05, (diet effect) P < 0.05, 2-way ANOVA and multiple comparison of genotype, diet and 
interaction by Bonferroni’s post hoc test. 
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Figure 7. DDOST+/- mice exhibit increased ketogenesis. (A) Concentrations of serum amino 
acids. (B) Heat map representation of SWATH-MS proteomics data for enzymatic pathways 
involved in ketogenesis. Significant proteins are represented as the Log2 fold change where red 
indicates a decreased and blue indicates an increase in protein concentrations. Data represented as 
means ± SD (n = 4-9/group). For proteomics, MSstatsV3.5.1 determined significant (P < 0.05) log 
fold changes in the protein intensities between the selected experimental group the WT low AGE 
diet group. 
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Tables. 
Table 1. Biochemical measurements in mice post-diet modifications (32 weeks of age).  Mean 
and standard deviation for biochemical measurements of each genotype during pre- and post-diet 
modification. Post-diet modification significance levels were determined by two-way ANOVA, 
testing the effect of genotype and diet. Differences between variables identified by Bonferroni’s 
post hoc test. Bold P values indicates significant effect of at least < 0.05. G: Genotype; D: Diet; 
G∙D: Interaction. 
 
 
 
Post-diabetes modification 
  
WT DDOST+/- Two-Way ANOVA 
AGELow AGEHigh AGELow AGEHigh G D G∙D 
Fed 
Glucose 
(mmol/L) 
15.70 ± 1.80 13.77 ± 1.53 15.66 ± 1.38 13.95 ± 1.18 0.96 0.23 0.94 
Fasting 
Glucose 
(mmol/L) 
10.65 ± 0.46 9.417 ± 1.13 9.913 ± 0.76 10.03 ± 0.47 0.94 0.49 0.96 
Fasting 
Insulin 
(ng/ml) 
1.255 ± 0.41 1.837 ± 0.53 
0.9438 ± 
0.27 
0.7999 ± 0.14 0.05 0.51 0.28 
Fasting 
Glucagon 
(pg/ml) 
1366 ± 187.8 2087 ± 287.6 1552 ± 80.13 1677 ± 279.8 0.61 0.09 0.93 
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Supplementary Materials and Methods. 
 
Genotyping of genetic knock-in mutation for DDOST+/- mice. All genotyping was confirmed with 
genomic Southern blot hybridization using the ScaI and the 5’ probe. Mice were then re-screened 
with the same filter with a generic Cre probe to determine whether they contain the ubiquitous 
promoter (Supporting Fig. 1). 
 
Pre-designed TaqMan Gene Expression Assays® IDs 
Gene name Life Technologies Assay ID 
Acadm Mm01323360_g1 
Acadvl Mm00444293_m1 
Acox1 Mm01246834_m1 
ADRB2 Hs00240532_s1 
Col1a1 Mm00801666_g1 
Col3a1 Mm01254476_m1 
Ccl2 Mm00441242_m1 
Ddost Mm00492100_m1 
DDOST Hs00193263_m1 
G6pc Mm00839363_m1 
Gcgr Mm00433546_m1 
Got1 Mm01195792_g1 
Gyk Mm00433896_m1 
Kcnma1 Mm01268569_m1 
Lepr Mm00440181_m1 
Pck1 Mm01247058_m1 
Pck2 Mm00551411_m1 
Ppara Mm00440939_m1 
Slc27a4 Mm01327405_m1 
Slc37a4 Mm00484574_m1 
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Supporting Figures and Figure Legends. 
 
 
Supporting Figure 1. Generation of a ubiquitous DDOST heterozygous knock-in mutant. (A) 
Genomic clone of DDOST bearing exon 1 used for the construction of the floxed targeting vector as 
indicated (top). Heterozygous mice were crossed with mice expressing Cre and subsequent progeny 
contained a ubiquitous over-expression allele. Genomic Southern blotting confirmed the predicted 
DDOST allelic structures in the ubiquitous knock-in strain (bottom). Left and middle panels: ES 
cell clones bearing indicated mutant DDOST allele in comparison to the parental wild-type ES 
cells; Right panels: adult mouse genotypes with either DDOST germline modifications or wild-
type, successfully crossed with the Ubi-Cre (UbiC) strain. (B) Hepatic gene expression of DDOST, 
encoding for human DDOST by real-time-PCR. (C) Hepatic gene expression of Ddost and DDOST, 
encoding for mouse AGE-R1 and human AGE-R1 respectively by real-time-PCR. (D) Targeted 
SWATH proteomics for OST48 protein content in gut tissue and an average of 5 different tissues 
(left kidney, liver, skeletal muscle, left ventricle and epididymal fat). (E) Endogenous mouse 
DDOST and human DDOST (striped) protein content measured in hepatic plasma membrane by 
ELISA 
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Supporting Figure 2. DDOST+/- mice do not have differences in body weight or body composition 
pre-diet modification. (A) Body weight. (B) Lean body mass percentage measured by EchoMRI. 
(C) Fat mass percentage measured by EchoMRI. Data represented as means ± SD (n = 4-9/group). 
 
 
Supporting Figure 3. SWATH-MS protein intensities of oxidative stress pathway related proteins 
and inflammatory pathway related proteins. (A) GPX1 (left) and ACON (right). (B) CD47 (left) 
and HA1D (right). Data represented as means ± SD (n = 4-9/group). *P < 0.05, MSstatsV3.5.1 
determined significant log fold changes in the protein intensities between the selected experimental 
group and the WT low AGE diet group. 
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Supporting Figure 4. Glycosylation occupancy in serum proteins. ((A) Peptide-centric glycosylation 
occupancy at asparagine residues in mouse serum proteins measured after trypsin digest. 
Glycosylation occupancy was measured at different glycosylation sites (e.g. THHY N188, Asn118 
in TTHY) in wild-type and AGE-R1 mice. Color is mapped to the extent of glycosylation 
occupancy from 100% (blue) to 0% (red). Data is mean (n = 3/group of 3 replicates). (B) Heat map 
representing several proteins secreted from the liver and their degree of glycosylation occupancy. 
(C) Extracted ion chromatograms for the peptide containing ESTN N377 in liver extracts; 
corresponding to de-glycosylated (dashed) and non-glycosylated (solid) forms of tryptic peptide 
(m/z of 826.4297 and m/z of 826.1017, respectively), peak corresponds to the monoisotopic peak 
from each peptide. 
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Supporting Figure 5. Real-time PCR of liver tissue targeting genes of interest. Acadm (left) and 
Acadvl (right). Data represented as means ± SD (n = 4-8/group in triplicate). 
 
 
Supporting Figure 6. Young DDOST+/- mice have impaired glucose tolerance. Young (8 week old) 
WT (●) and AGE-R1 (●) mice serum glucose and insulin levels in mice fasted for 6 hours following 
intraperitoneal insulin or glucose injection. (A) ipGTT measuring glucose homeostasis (top) with 
subsequent area-under-the-curve (AUC) analysis (bottom). (B) ipITT assessing glucose 
effectiveness (top) and ratio of AUIC:AUGC of early-phase insulin response (bottom). (C) ipGTT 
measuring  insulin effectiveness (top) with subsequent area-under-the-curve (AUC) analysis 
(bottom).  Data represented as means ± SD (n = 4-9/group). *P < 0.05, student’s t-test. 
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Supporting Figure 7. DDOST+/- mice exhibit impaired first phase insulin secretion. (A-B) 
Intraperitoneal glucose and insulin tolerance testing in wild-type (●) and DDOST+/- (●) mice fasted 
for 6 hours after 24 weeks of high or low AGE diet feeding. (A) ipITT (left) and ipGTT (right) 
measuring glucose homeostasis and (B) ipGTT measuring insulin effectiveness with subsequent 
area-under-the-curve (AUC) analysis of serum glucose (AUGC) and insulin (AUIC). (C) Fasted 
insulin concentrations in plasma serum (top). Ratio of AUIC:AUGC to determine insulin 
effectiveness during the first phase insulin secretion response (bottom). Data represented as means 
± SD (n = 4-9/group). #P < 0.1, *P < 0.05, **P < 0.01, α (genotype effect) P < 0.05, β (diet effect) 
P < 0.05, δ (interaction effect) P < 0.05, 2-way ANOVA and multiple comparison of genotype, diet 
and interaction by Bonferroni’s post hoc test. 
 
 
Supporting Figure 8. Serum concentrations of amino acids. Amino acid metabolite concentration 
measured in plasma serum. A (genotype effect) P < 0.05, B (diet effect) P < 0.05, C (interaction 
effect) P < 0.05, 2-way ANOVA and multiple comparison of genotype, diet and interaction by 
Bonferroni’s post hoc test. 
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Chapter 4: Globally elevating the 
AGE clearance receptor, OST48 
does not protect against the 
development of diabetic kidney 
disease, despite improving insulin 
secretion. 
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Introduction to this chapter. This chapter is submitted for publication in Scientific Reports as an 
original article. It has currently been peer-reviewed and is under revisions prior to publication. In 
this report, we over-expressed the gene encoding for oligosaccharyltrasnferase-48 (OST48). 
Although the current literature has suggested that increasing OST48 could be a potential mechanism 
to decrease systemic AGE toxicity by facilitating AGE clearance from the body, in diabetic 
complications, there has been little evidence published to directly support this claim. Therefore, the 
focus of this chapter is to elucidate whether increased OST48 could prevent the development of 
diabetic kidney disease. Furthermore, beyond the scope of this chapter, this work provides crucial 
information in elucidating the role of OST48 in the kidney. In this novel study, over-expression of 
OST48 did not protect against the development of diabetic kidney disease and diabetic mice 
proceeded to develop glomerulosclerosis, tubulointerstitial fibrosis and kidney function decline. 
 
Specifically, we demonstrated the following; 1) Mice over-expressing OST48 (DDOST+/-) and 
wild-type mice induced with experimental diabetes both exhibited kidney injury and declined 
kidney function. 2) Increased urinary excretion of AGEs and reduced kidney deposition in 
DDOST+/- diabetic mice did not translate into protection against kidney damage and dysfunction. 
3) Diabetic DDOST+/- mice exhibited significant improvements in fasting plasma insulin, insulin 
sensitivity and short-term glucose homeostasis. 4) However, this did not improve long-term 
glycaemic control.  
 
In summary, in this group of experiments we showed conclusively that increased OST48 in the 
kidney does not protect against the development of diabetic kidney disease. The data however 
suggests that OST48 may influence insulin sensitivity and insulin secretion and that further studies 
are required to elucidate the role OST48 has in the kidney.  
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Abstract 
The accumulation of advanced glycation end products (AGEs) have been implicated in the 
development and progression of diabetic kidney disease (DKD). There has been interest in 
investigating the potential of AGE clearance receptors, such as oligosaccharyltransferase-48kDa 
subunit (OST48) to prevent the detrimental effects of excess AGE accumulation seen in the diabetic 
kidney. Here the objective of the study was to increase the expression of OST48 to examine if this 
slowed the development of DKD by facilitating the clearance of AGEs. Groups of 8-week-old 
heterozygous knock-in male mice (n=9-12/group) over-expressing the gene encoding for OST48, 
dolichyl-diphosphooligosaccharide-protein glycosyltransferase (DDOST+/-) and litter mate controls 
were randomised to either (i) no diabetes or (ii) diabetes induced via multiple low-dose 
streptozotocin and followed for 24 weeks. By the study end, global over expression of OST48 
increased glomerular OST48. This facilitated greater renal excretion of AGEs but did not affect 
circulating or renal AGE concentrations. Diabetes resulted in kidney damage including lower 
glomerular filtration rate, albuminuria, glomerulosclerosis and tubulointerstitial fibrosis. In diabetic 
mice, tubulointerstitial fibrosis was further exacerbated by global increases in OST48. There was 
significantly insulin effectiveness, increased acute insulin secretion, fasting insulin concentrations 
and AUCinsulin observed during glucose tolerance testing in diabetic mice with global elevations in 
OST48 when compared to diabetic wild-type littermates. Overall, this study suggested that despite 
facilitating urinary-renal AGE clearance, there were no benefits observed on kidney functional and 
structural parameters in diabetes afforded by globally increasing OST48 expression. However, the 
improvements in insulin secretion seen in diabetic mice with global over-expression of OST48 and 
their dissociation from effects on kidney function warrant future investigation.
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Introduction 
Currently, the world is faced with a pandemic of both type 1 and type 2 diabetes (T1D and T2D)10, 
233, defined by persistent hyperglycaemia, which is a predominant factor in the development of 
concomitant complications12, 234. A major complication, diabetic kidney disease (DKD) is a 
worldwide health concern and is an important risk factor for end-stage renal disease (ESRD)235 and 
cardiovascular disease234, 236. Understanding the pathophysiology of DKD development and 
progression is therefore, a key challenge to reduce the burden of diabetic complications. The early 
clinical presentation of DKD is characterised by hyperfiltration, progressive proteinuria and 
associative glomerular injury accompanied by tubulointerstitial fibrosis and in the later stages, a 
steady progressive decline in renal function13. Unfortunately, despite optimal clinical management, 
involving both glycaemic16, 237 and blood pressure control17, including inhibitors of the renin-
angiotensin-aldosterone system238, 239, it is only possible to achieve a 30% improvement in declining 
kidney function in DKD. Despite intervention, many individuals reach end stage disease requiring 
renal replacement therapy or die prematurely from a cardiovascular event240. Hence new therapies 
to combat DKD are urgently required.  
 
AGE accumulation within tissues is thought to one pathological mediator in DKD241. It is 
postulated that under physiological conditions, OST48 may facilitate AGE clearance into the urine53 
and that this function is impaired during the development and progression of DKD241 resulting in 
pathological accumulation of AGE at sites such as the kidney.  OST48 (also known as AGER1) 
dually functions as an extracellular AGE binding protein242 and as a 48kDa subunit that functions as 
part of the oligosaccharyltransferase complex, which mediates the transfer of high-mannose 
oligosaccharides to asparagine residues within the lumen of the rough ER. OST48 gene and protein 
expression are decreased by diets abundantly rich in AGEs51 and by diabetes50, 52.  In addition, there 
are associations between lower OST48 levels in circulating immune cells and progressive diabetic 
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nephropathy in a small cohort of patients with type 1 diabetes49, 243 and with impaired insulin 
sensitivity patients with in type 2 diabetes54, 74. To date, there has been one, in vivo investigation 
using untargeted over-expression of OST48. This study in elderly mice (>500 days old) 
demonstrated improvements in longevity, insulin sensitivity and resistance to balloon injury in 
blood vessels64. However, there are no studies where the efficacy of increasing OST48 expression 
to facilitate AGE clearance has been tested in the development of kidney disease including DKD.  
 
A SNP array from the FinnDiane population study (n = 2719) inferred that there was an association 
of the OST48 gene, DDOST (rs2170336), with nephropathy development in individuals with T1D55. 
Additionally, a study in T1D patients identified that elevated serum AGEs were associated with 
increased OST48 mRNA in circulating mononuclear cells49. Moreover, the functional loss of 
DDOST in humans, demonstrates a phenotype with characteristics known as congenital disorders of 
glycosylation (CDG)57. A sole case was described in a seven-year-old male child with CDG, whose 
condition arose from the inheritance of a maternal missense mutation and a paternal point mutation 
resulting in a premature stop codon and as a result the patient exhibited severe hypoglycosylation57. 
It was shown however that restored wild-type DDOST cDNA in the patients’ fibroblasts rescued 
glycosylation, thus indicating the importance of functional DDOST in a pathological environment57. 
 
For the present study, we hypothesised that mice with a global OST48 overexpression would be 
protected from increases in circulating AGEs and impaired kidney function in the context of 
diabetes.  Specifically, we aimed to identify whether increased OST48 in the presence of 
hyperglycaemia could drive AGE lowering to protect against AGE-mediated microvascular damage 
typically seen in DKD, such as glomerular pathology and greater tubulointerstitial fibrosis.   
 
Results  
 
Characterisation of diabetes in a site directed global OST48 knock-in mouse model. Mice were 
generated with a global over-expression of OST48 (DDOST+/-)244. These mice exhibited variation 
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in food and water consumption, urine output and a significant reduction in kidney weight compared 
with wild-type mice (Table 1). Diabetes was characterised by elevated GHb, fed/fasting blood 
glucose and increased fasting insulin (Table 1). Diabetic mice had significantly lower mean total 
body weight, increased urine output as well as increased food and water consumption and renal 
hypertrophy (Table 1).  
 
Increased glomerular OST48 facilitated AGE urinary excretion in DDOST+/- mice. SWATH 
proteomics in renal cortices enriched for glomerular proteins identified that non-diabetic DDOST+/- 
mice had a significant increase in OST48 protein abundancy (48.39-fold increase) over non-diabetic 
wild-type mice (Figure 1A). There was also a tendency toward increased OST48 protein in 
glomerular fractions from diabetic DDOST+/- mice (P=0.07; 14.44-fold increase) compared to 
diabetic wild-type mice (Figure 1A). Surprisingly, there was no significant increase in OST48 seen 
in tubular enriched protein fractions (Figure 1B) from DDOST+/- mice (Figure 1C). Glomerular 
OST48 appeared to be predominately expressed by podocytes as indicated by the co-localisation of 
nephrin (Figure 1D) as well as within proximal tubule cells expressing SGLT2 (Figure 1E). 
Subsequently, there was a significant increase in renal AGE excretion by all diabetic mice as well 
as the non-diabetic DDOST+/- mice (Figure 1F). Specifically, urinary AGE excretion increased by 
~120% in non-diabetic DDOST+/- mice compared to wild-type mice (Figure 1F; P=0.033). 
However, DDOST+/- mice showed no increases in AGE accumulation in either kidney tissue 
(Figure 1G) or within the circulation (Figure 1H). 
 
Diabetic DDOST+/- mice had no improvements in kidney function despite increased urinary 
AGE excretion. All diabetic mice had impaired kidney function as ascertained by a decrease in 
creatinine clearance (Figure 2A), which was not affected by OST48 overexpression. Diabetic mice 
also had albuminuria when assessed by either albumin:creatinine ratio (Figure 2B) or 24 hour 
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urinary albumin excretion (Figure 2C). Therefore, increased OST48 expression did not prevent the 
decline in kidney function which is characteristic of diabetic kidney disease. 
 
Globally increasing OST48 expression did not protect against diabetes-induced kidney 
structural damage. Diabetes resulted in glomerulosclerosis in both genotypes to the same degree 
by the study end (Figure 3A). This was supported by SWATH proteomics data from kidney 
cortices enriched for glomerular proteins which demonstrated significant increases in the abundance 
of collagen proteins in diabetic mice (Figure 3B). Increasing the expression of OST48 also did not 
prevent tubulointerstitial fibrosis (TIF) in the kidneys of diabetic mice, as seen with Masson’s 
trichrome (Figure 3C) and Sirius red (Figure 3D) staining. Indeed, there was exacerbation of TIF 
in diabetic DDOST+/- by comparison to diabetic wild-type littermates (Figure 3D; 32.0% increase, 
P=0.043). 
 
Diabetic mice with globally increased OST48 expression have greater insulin secretory 
capacity and increased P13K-AKT activity in glomeruli, which is dissociated from 
deterioration in kidney function. In the absence of diabetes, globally increasing the expression of 
OST48 had no significant effect on insulin sensitivity or glucose tolerance (Figure 4A-G). 
However, when diabetes was induced, mice with a global over-expression of OST48 had significant 
reduction in fractional glucose excretion (Figure 4A), increases in fasting plasma insulin (Figure 
4B) and lower blood glucose concentrations during an ipGTT, both acutely at 15 minutes (11.9% 
decrease, P = 0.097) and 30 minutes (14.2% decrease, P = 0.017) post-bolus of D-glucose (Figure 
4C). Consistent with these changes, overall insulin secretion (Figure 4D; average 77.4% increase, 
P < 0.05 – 0.001), first phase insulin secretion (Figure 4E, 99.5% increase, P = 0.0005) and the 
AUC insulin (Figure 4F) during the ipGTT were all greater in diabetic mice over expressing 
OST48, when compared to littermate wild type diabetic mice. Insulin effectiveness (AUIC:AUGC) 
was also greater in diabetic DDOST+/- mice compared to diabetic wild-type mice (Figure 4E-G; 
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99.5% increase, P=0.0005). During fed conditions an insulin tolerance test (ipITT), all diabetic 
DDOST+/- mice had decreased responsiveness to insulin with persistently elevated plasma glucose 
concentrations, when compared to non-diabetic mice (Figure 4H) but did not differ between 
genotypes. This was particularly evident during the first 60-minutes of the ipITT, where there was a 
rapid decline in plasma glucose concentrations in non-diabetic mice (Figure 4H-I; 490% decline 
compared to diabetic mice), with rapid recovery of blood glucose concentrations by 120 mins. This 
increase in insulin secretion and effectiveness was also confirmed by increased PI3K-AKT 
activation in the glomerular enriched fractions from mice over-expressing OST48 Figure 4J). 
 
Discussion 
There has been some speculation that increasing AGE clearance via increases in OST48 could 
alleviate the development and progression of diabetic kidney disease49, 51, 52, 59, 60. We have shown 
for the first time that globally increasing OST48 through the over-expression of DDOST in a mouse 
model of diabetes, did not protect against kidney disease. Indeed, there was an exacerbation of 
tubulointerstitial fibrosis seen in diabetic mice with a global over-expression of OST48. Quite 
surprisingly, however, this was despite significant improvements in insulin secretory capacity and 
action in these diabetic DDOST+/- mice. Therefore, this study dissociated improvements in 
insulin secretion from slowing the onset and progression of DKD, in mice over-expressing 
OST48. 
 
Previous studies have suggested that increasing AGE clearance from the body through the OST48 
pathway prevents oxidative stress51 and inflammatory responses9, as well as improving healing and 
hyperglycaemia64, concluding that increased OST48 activity could have potential benefits to 
alleviate vascular complications in diabetes51, 60 including DKD9, 51. Moreover, previous studies 
have alluded at the potential benefits of AGE restriction and reducing serum AGE levels in diabetic 
patients4, 74, 245, 246, and suggested that AGE excretion facilitated through increased OST48 could 
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reduce the AGE burden53, 64, 71, 74, 247. Hence, we were surprised that increasing AGE clearance by 
the kidneys, via globally increasing OST48 expression had no effect on kidney function and 
structural parameters in this mouse model of diabetes and worsened renal pathology.  
 
In our mouse model the lack of effect of OST48 to alleviate DKD was despite modest 
improvements to insulin secretory capacity, although this was not sufficient to improve the long-
term markers of glycaemic control (GHb), nor fasting and fed plasma glucose concentrations. 
However, our data is in agreement with the DCCT/EDIC clinical trials, which indicate that without 
effective reduction in blood glucose early in disease development, there was no reduction in the risk 
in development of diabetic vascular complications including DKD248, 249. There have been previous 
studies where AGEs have been shown to impair insulin secretion70, 250 although it is unclear as to 
the role that OST48 plays in beta cells. However, we have identified that OST48 is expressed in 
beta cells251. In addition, further investigation would be required to elucidate why these apparent 
improvements in insulin secretion seen in diabetic OST48 mice did not translate to improved long-
term clinical markers of glycaemic control. However, this may just indicate that modest 
improvements in insulin secretion later in disease are not sufficient to alter the progression of 
diabetic kidney disease. 
 
There was also a decline in renal AGE content seen with diabetes, which was consistent with the 
increases in AGE excretion into the urine, but this was not affected by OST48. In agreement with 
our findings, another study showed that increasing OST48 expression in mice also facilitated 
urinary AGE clearance, without affecting renal AGE concentrations64. This would suggest that 
rather than specific AGE uptake into the kidney the flux of AGEs through the kidney into the urine, 
may trip signalling cascades for other AGE receptors such as RAGE252. This could be feasibly 
responsible for the observed glomerulosclerosis and tubulointerstitial fibrosis253 with diabetes and 
with OST48 overexpression where chronic binding of circulating AGEs to RAGE results in diabetic 
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kidney and cardiovascular disease136, 246, 253. Increased AGE flux from the circulation to the urine, is 
also postulated in other studies to have detrimental effects on proximal tubules contributing to 
tubulointerstitial fibrosis254, which is consistent with our model. However, we do not suspect 
defects in protein N-glycosylation contributed to the kidney pathology seen with OST48 
overexpression 255. This is because, we have previously shown that ubiquitous global 
overexpression of OST48 does not impair nor alter protein N-glycosylation244.  
 
Despite the ineffectiveness of increased OST48 to protect against the development of diabetic 
kidney disease, we did however observe benefits on insulin secretion, fasting insulin and insulin 
sensitivity by globally elevating OST48 in diabetic mice. Our data suggests that downstream insulin 
receptor activity via P13K and diverging into increased lipogenesis, glycolysis and glycogenesis 
(starch and sucrose metabolism) occurs in the kidney when OST48 is increased. Our data is in 
concordance with previous human studies which suggest that AGE restriction whether through 
dietary74 or therapeutic245 methods improve insulin sensitivity and decrease in serum OST48 
concentrations74.  We have also consistently shown that AGE lowering therapies which decrease the 
burden of AGEs improve both insulin secretion70 and improve insulin sensitivity72, 256.  
 
In summary, these studies revealed that increasing OST48 expression globally does not prevent the 
development of DKD. Specifically, in diabetic mice, increasing OST48 expression did not prevent 
the decline in kidney function, glomerulosclerosis and exacerbated tubulointerstitial fibrosis. 
Therefore, we would suggest that increasing the flux of AGEs into the urine is not a strategy worth 
pursuing in DKD. Similarly, it appears that increasing AGE signalling in the kidney via receptors 
such as RAGE without increasing kidney AGE content, is responsible for this lack of protective 
effect. Therefore, this study suggests that globally increasing the expression of OST48 thereby 
increasing urinary AGE excretion does not improve kidney function in the context of diabetes. 
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However, further studies are required to identify whether kidney cell-specific modulation of OST48 
may be superior to a global approach.  
 
Materials and Methods  
Animal husbandry. Male C57BL/6J wild-type mice and littermate heterozygotes with a ubiquitous 
genetic insertion of the human gene encoding AGE-R1/OST48 (DDOST+/-) at the ROSA26 locus 
(ROSA26tm1(DDOST)Jfo; termed as DDOST+/-) were generated (Ozgene, Australia). Between 6-8 
weeks of age (Week 0), diabetes was induced in male wildtype (n = 9) and DDOST+/- (n = 9) mice 
by multiple low dose intraperitoneal injections of streptozotocin (STZ)257, at a dosage of 
55mg/kg/day (dissolved in sodium citrate buffer, pH 4.5) for 5 consecutive days. Control or non-
diabetic male wild-type (n = 11) or DDOST+/- (n = 12) mice received equivalent injections of 
sodium citrate buffer alone. After 10 days of recovery, blood glucose concentrations were 
determined and then repeated weekly to ensure mice included were diabetic (blood glucose 
concentrations > 15mmol/L). Mice were housed in specific pathogen free housing conditions and 
allowed access to food and water ad libitum and were maintained on a 12 hour light:dark cycle at 
22°C. All mice received a diet of standard mouse chow low in AGE content (AIN-93G70; Specialty 
Feeds, Australia) ad libitum. At 0 and 12 weeks of the study, mice were housed in metabolic cages 
(Iffa Credo, l’Arbresle, France) for 24 hours to determine food and water consumption. Urine 
output was also measured during caging and urinary glucose determined by a glucometer 
(SensoCard Plus, POCD, Australia). 
 
Intraperitoneal glucose and insulin tolerance testing (IPGTT/IPITT). Intraperitoneal glucose 
(ipGTT) and insulin (ipITT) tolerance tests were performed as outlined previously230. Briefly, for 
ipGTT experiments, mice were fasted for 6 hours and a 1g/kg bolus of glucose was injected 
intraperitoneally (ip) and 50µl of blood was sampled at 0, 15, 30, 60, and 120 mins for plasma 
glucose and insulin analysis. During ipITT experiments, mice were injected with 1.0U of fast acting 
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insulin/kg (Humulin) diluted in 0.9% saline and 50µl of blood was sampled at 0, 30, 60, and 120 
mins for plasma glucose analysis. 
 
Liquid Chromatography-Mass Spectrometry (LC-MS/MS). As previously described224, proteins 
were extracted from whole liver tissue samples using guanidine denaturing buffer (6 M 
guanidinium, 10 mM DTT and 50 mM Tris-HCl). Reduced cysteines were alkylated with 
acrylamide, and quenched with excess DTT. Proteins were precipitated in 4 volumes of 1:1 
methanol:acetone and digested with trypsin. Peptides were desalted and analysed by Information 
Dependent Acquisition LC-MS/MS as described225 using a Prominence nanoLC system (Shimadzu, 
NSW, Australia) and Triple TOF 5600 mass spectrometer with a Nanospray III interface (SCIEX). 
SWATH-MS analysis was performed226 and analysed with MSstats as previously described. 
Differentially abundant proteins were analysed using DAVID227. 
 
Serum/urine creatinine and clearance. Serum and urinary creatinine were measured 
spectrophotometrically at 550nm (Cobas Mira, Roche Diagnostics, Australia), and the ratio of 
creatinine clearance was determined as specific measure of renal function. 
 
Albumin excretion rate. Urine albumin was measured spectrophotometrically at 620nm 
(FLUOstar Optima, BMG Labtech, Australia), and 24-hour albumin excretion rate was calculated 
by normalizing the levels of albumin to the flow rate of urine. 
 
Histology and imaging. Paraffin-embedded sections were stained with either a Periodic acid Schiff 
(PAS) staining kit (Sigma-Aldrich, United States), a Trichrome (Masson) staining kit (Sigma-
Aldrich, St. Louis, Missouri, USA) or Sirius Red (Sigma-Aldrich, United States). All sections were 
visualized on an Olympus Slide scanner VS120 (Olympus, Japan) and viewed in the supplied 
program (OlyVIA Build 10555, Olympus, Japan). Slides were quantified based on threshold 
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analysis in Fiji258. Briefly, for immunofluorescence staining, paraffin-embedded sections were 
stained with a combination of either anti-CML (1:200 dilution; ab27684; Abcam, United Kingdom), 
OST48 (H-1; 1:100 dilution; SC-74408; Santa Cruz biotechnologies, United States), nephrin (1:100 
dilution; ab27684; Abcam, United Kingdom) and SGLT2 (M-17; 1:100 dilution; sc-47403; Santa 
Cruz biotechnologies, United States). Confocal images were visualized on an Olympus FV1200 
confocal microscope (Olympus, Japan) and viewed in the supplied program (FV10, Olympus, 
Japan). 
 
Glomerulosclerotic index (GSI). GSI as a measure of glomerular fibrosis was evaluated in a 
blinded manner by a semi-quantitative method259. Severity of glomerular damage was assessed on 
the following parameters; mesangial matrix expansion and/or hyalinosis of focal adhesions, true 
glomerular tuft occlusion, sclerosis and capillary dilation. Specifically, grade 0 indicates a normal 
glomerulus; 1, <25% glomerular injury; grade 2, 26-50%; grade 3, 51-75%; and grade 4, >75%. 
 
Statistical Analyses. Results are expressed as mean ± SD (standard deviation), and assessed in 
GraphPad Prism V7.01 for Windows (GraphPad Software, United States). Normally distributed 
parameters (tested with D’Agostino & Pearson omnibus normality test) were tested for statistical 
significance by 2-way ANOVA followed by post hoc testing for multiple comparisons using the 
Bonferroni method unless otherwise specified. For comparison between groups as required, a two-
tailed unpaired Student’s t-test was used where specified. For SWATH-MS, MSstatsV3.10.0260 was 
used to detect differentially abundant proteins estimating the log-fold changes between compared 
conditions of the chosen experimental group and with the wild-type non-diabetic mice. For all 
calculations, a P < 0.05 was considered as statistically significant. 
 
Experimental animal ethics statement. All animal studies and experiments were performed in 
accordance with guidelines provided and approved by the AMREP (Alfred Medical Research and 
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Education Precinct) Animal Ethics Committee and the National Health and Medical Research 
Council of Australia (E/0846/2009B). 
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Figures and Figure Legends 
 
Figure 1.  DDOST+/- mice have increased glomerular expression of OST48, increased CML 
excretion, however no changes in CML deposition in the kidney or plasma CML levels. 
OST48 expression and localization in the kidney. SWATH proteomics (A-C) quantification of the 
protein intensities of OST48 in processed kidney tissue enriched for either (A) glomeruli or (B) 
tubules and in the kidney cortex (C). Confocal photomicrographs (D-E) of OST48 (green), CML 
(orange) and either a podocyte foot process marker, nephrin (red) or a proximal tubule marker, 
SGLT2 (red) on kidney sections imaged at either a (D) glomerulus or (E) proximal tubule. CML 
ELISA (F-H) measuring the total content of CML in (F) 24-hour urine collections, (G) whole 
kidney and (H) plasma. Results are expressed as mean ± SD with either two-way ANOVA or 
unpaired t-test analysis (n = 4-9) *P < 0.05. Scale bars from representative images for confocal 
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microscopy are representative of 5µm. For proteomics, MSstatsV3.10.0 determined significant (P < 
0.05) log fold changes in the protein intensities between the selected experimental group the wild-
type non-diabetic group (n = 4-5). 
 
 
Figure 2.  Diabetic mice with global increases in OST48 are not protected against the 
development of diabetic kidney disease. Serum and 24-hour urine was collected from mice in 
metabolic cages at week 0 and week 24 of the study. Creatinine was measured 
spectrophotometrically and the (A) change in creatinine clearance over the study period was 
determined from matched creatinine clearance values from week 0 of the study (6-8 weeks of age) 
to week 24 of the study. (B) Urinary albumin:creatinine ratio measured at week 24 of the study. (C) 
Albumin was measured spectrophotometrically at 620nm in a biochemical analyzer and the albumin 
excretion rate (AER) was determined based on the 24-hour urine flow rate. Results are expressed as 
mean ± SD with either two-way ANOVA or paired t-test analysis (n = 3-8) *P < 0.05. 
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Figure 3.  DDOST+/- mice were not protected from renal structural damage and exhibited 
similar patterns of collagen protein content exhibited in mice with diabetes. (A) Assessment of 
renal glomerular damage in the kidney with Periodic-acid Schiff staining (PAS), which was then 
quantified based on a positive threshold protocol. DDOST+/- mice and mice with a diabetic 
phenotype exhibited moderate glomerulosclerosis, indicated by an increase in mesangial matrix 
expansion (black arrow). (B) Heat map representation of SWATH-MS proteomics of glomeruli 
enriched proteins for enzymatic pathways involved in collagen fibril organization. Significant 
proteins are represented as bolded cells, where red indicates an increase and blue indicates a 
decrease in protein concentrations. (C) Presence of collagen in Masson’s trichrome (blue staining) 
and (D) Sirius red (red staining) in the interstitium of the tubules (black arrow) is an indicator of 
progressive kidney damage. The severity of these changes was more pronounced in mice with a 
diabetic phenotype. Scale bars from representative images of (A) glomeruli stained with PAS or (C-
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D) tubule sections stained with either Masson’s trichrome or Sirius red were 20µm and 100µm, 
respectively. Results are expressed as mean ± SD with either two-way ANOVA or unpaired t-test 
analysis (n = 5-9) *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. For proteomics, 
MSstatsV3.10.0 determined significant (P < 0.05) log fold changes in the protein intensities 
between the selected experimental group the wild-type non-diabetic group (n = 3-5). 
 
Figure 4. Diabetic DDOST+/- mice exhibit increased first phase insulin secretion and 
activation of the P13K-AKT pathway akin to a diabetic phenotype. (A) 24-hour fractional 
excretion of glucose. (B) Fasting plasma insulin concentrations. (C) Plasma glucose and (D) insulin 
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curve over 120-minutes following an intraperitoneal glucose injection and (E) first phase area-
under-the-curve (AUC) analysis and (F) 120-minute AUC analysis. (G) Ratio of AUIC:AUGC of 
early-phase insulin response. (H) Plasma glucose over 120-minutes following an intraperitoneal 
insulin injection and (I) 120-minute AUC analysis. (J) Heat map representation of SWATH-MS 
proteomics data for enzymatic pathways in glomerular proteins involved the P13K-AKT signalling 
pathway. Significant proteins are represented as the Log2 fold change where red indicates a 
decreased and blue indicates an increase in protein concentrations. Results are expressed as mean ± 
SD with either two-way ANOVA or unpaired t-test analysis (n = 5-9) *P < 0.05, **P<0.01, 
***P<0.001. For IPGTT and IPITT curves results are represented as *P<0.05, **P<0.01, 
***P<0.001 for DDOST+/- diabetic compared to wild-type diabetic, α < 0.05 effect due to 
genotype, β < 0.05 effect due to diabetes. For proteomics, MSstatsV3.5.1 determined significant (P 
< 0.05) log fold changes in the protein intensities between the selected experimental group the wild-
type non-diabetic group (n = 3-5). 
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Tables 
Table 1. Biochemical/anthropometric measurements post-diabetes (Week 24 of study/32 
weeks of age).  Mean and standard deviation for biochemical/anthropometric measurements (n = 5-
11). Significance levels were determined by two-way ANOVA, testing the effect of genotype and 
diabetes. Differences between variables identified by Bonferroni’s post hoc test. Bold P values 
indicates significant effect of at least < 0.05. 
 
  
WT DDOST+/- Two-Way ANOVA 
Control Diabetic Control Diabetic Genotype Diabetes Interaction 
GHb 
(mmol/mol) 
5.58 ± 
0.36 
11.75 ± 
2.41 
6.54 ± 
1.21 
10.39 ± 
2.46 
0.36 <0.0001 0.17 
Food 
consumption 
(g/24 h) 
0.067 ± 
0.016 
0.31 ± 
0.058 
0.078 ± 
0.026 
0.20 ± 
0.082 
0.014 <0.0001 0.0033 
Fed Glucose 
(mmol/L) 
16.26 ± 
2.43 
25.30 ± 
6.22 
16.26 ± 
3.18 
27.25 ± 
1.50 
0.52 <0.0001 0.52 
Fasting 
Glucose 
(mmol/L) 
10.79 ± 
3.02 
12.98 ± 
2.51 
9.70 ± 
0.98 
12.35 ± 
1.91 
0.36 0.015 0.81 
Fasting Insulin 
(ng/ml) 
0.98 ± 
0.61 
0.33 ± 
0.07 
0.97 ± 
0.32 
0.71 ± 
0.15 
0.22 0.0056 0.21 
Water 
consumption 
(ml/24 h) 
0.13 ± 
0.010 
1.73 ± 
0.43 
0.15 ± 
0.052 
0.91 ± 
0.39 
0.00030 <0.0001 0.0002 
Urine 
production 
(ml/24 h) 
0.025 ± 
0.012 
1.37 ± 
0.43 
0.019 ± 
0.012 
0.77 ± 
0.33 
0.0030 <0.0001 0.0035 
Kidney 
Weight/BW 
ratio (g) 
11.92 ± 
2.99 
19.68 ± 
0.71 
10.71 ± 
1.94 
16.36 ± 
1.23 
0.020 <0.0001 0.25 
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Chapter 5: The AGE receptor, 
OST48 contributes to podocyte 
dysfunction in experimental 
diabetic kidney disease via 
induction of endoplasmic reticulum 
stress. 
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Introduction to this chapter. This chapter is submitted for publication in the Journal of the 
American Society of Nephrology as an original article. In this report, we over-expressed the gene 
encoding for oligosaccharyltransferase-48 (OST48) specifically in the podocytes. It is well known 
that podocytes are significantly reduced in diabetic kidney disease (DKD). In diabetes, podocytes 
are exposed to persistent long-term challenges, including; glomerular hypertension, metabolic 
imbalances and abnormal receptor stimulation, all of which are thought to contribute to functional 
loss of podocytes, compromising the integrity of the filtration barrier. The pathological events that 
culminate in diabetic kidney disease is thought to occur in a stereotypical manner that initiates with 
podocyte injury, leading tuft adhesions in the Bowmans capsule and subsequent filtration of 
abnormal filtrate encroaching the glomerulo-tubular junction and subsequent degradation of 
proximal tubules. There have been no studies examining whether specifically increasing AGE 
clearance via receptor manipulation in the podocytes is protective of the kidneys in diabetes. As 
such, we site-specifically increased podocyte expression of OST48.  
 
We demonstrated the following; 1) Mice over-expressing OST48 specifically at the podocytes 
(DDOST+/-Pod-Cre) exhibited elevated serum creatinine, reduced eGFR and increased albumin 
excretion, all of which at levels worse than wild-type diabetic mice. 2) This was not improved by 
increased AGE clearance via podocyte OST48. 3) Glomerular damage occurred including 
mesangial matrix expansion, increased collagen IV depo and substantial tubulointerstitial fibrosis. 
4) DDOST+/-Pod-Cre podocytes exhibited increased endoplasmic reticulum stress markers, 
specifically elevated sXBP1 and GRP78 expression. 
 
In summary, we demonstrated a novel OST48 pathway that leads to increased AGE excretion, 
however this did not prevent podocyte damage from occurring in the forms of endoplasmic 
reticulum stress markers GRP78 and sXBP1. All of which, culminating in the development of 
kidney disease. 
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Graphical abstract 
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Abstract 
The accumulation of advanced glycation end products (AGEs) is implicated in the development and 
progression of diabetic kidney disease (DKD). There has been considerable interest in targeting the 
AGE pathway by increasing “clearance” via modulating receptors such as advanced glycation end 
product receptor 1 (OST48). However, to date, no studies have examined whether stimulating AGE 
clearance via receptor manipulation is reno-protective in diabetes. Podocytes, which are involved in 
AGE clearance, are early contributors to DKD and could be a target for reno-protection. As such, 
we generated a mouse with targeted elevation of OST48 in podocytes driven by the podocin 
promoter (DDOST+/-Pod-Cre). Despite promoting increased urinary clearance of AGEs, increasing 
OST48 resulted in a decline in renal function, which was further exacerbated by diabetes. The 
resulting phenotype showed increased serum creatinine and decreased FITC-sinistrin glomerular 
filtration rates. DDOST+/-Pod-Cre mice had significant glomerular damage including 
glomerulosclerosis, collagen IV deposition, glomerular basement membrane (GBM) thickening and 
foot process effacement and tubulointerstitial fibrosis. SWATH-MS proteomic analysis of isolated 
glomeruli identified enrichment in collagen deposition, endoplasmic reticulum and oxidative stress 
proteins. Furthermore, ultra-resolution microscopy of podocytes revealed denudation of foot 
processes where there was co-localization of OST48 and AGEs. Electron microscopy confirmed 
that increasing OST48 expression led to podocyte foot process effacement and GBM expansion. 
These studies indicate that facilitating AGE clearance by increasing podocyte expression of OST48, 
results in glomerular endoplasmic reticulum stress and a decline in kidney function which worsened 
diabetic kidney disease. 
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Introduction 
Globally there is a rising pandemic of diabetes10, 11, defined by persistent hyperglycemia, a principal 
risk factor for the development of concomitant chronic complications2, 12. Hence, the numbers of 
individuals with diabetic kidney disease (DKD), a major complication, are burgeoning. DKD is an 
important risk factor for both end-stage kidney disease and cardiovascular disease1, 2. While renin-
angiotensin system blockade including angiotensin-converting-enzyme inhibition is first line 
therapy for DKD, in general these agents only achieve an ~ 20% reduction in end-stage kidney 
disease14.  
 
Advanced glycation end products (AGEs) are a heterogeneous and complex group of non-
enzymatic, post-translational modifications to amino acids and proteins, which include hemoglobin 
A1C (HbA1C) a clinical marker used for the diagnosis of diabetes. Their endogenous formation can 
be exacerbated by chronic hyperglycemia and oxidative stress 3 and therefore the accumulation of 
AGEs occurs at an accelerated rate in diabetes261, 262. Increases in AGE formation on skin collagen5, 
263, 264 and within the circulation265, 266 predict poor prognosis for patients with diabetes including 
increased risk for kidney and cardiovascular disease. The kidneys are a major site of AGE 
detoxification through the filtration of circulating AGEs, and subsequently their active uptake and 
excretion7, 8 and hence AGE accumulation is seen in diabetic patients with chronic kidney 
disease267, 268. Therapies which lower AGE accumulation have shown benefit in Phase II clinical 
trials for the treatment DKD in individuals with Type 2 diabetes42. 
 
OST48, an evolutionarily conserved type 1 transmembrane protein43, is encoded by the DDOST 
(Dolichyl-diphosphooligosaccharide—protein glycosyltransferase 48 kDa subunit) gene and has 
been postulated to function as a receptor for AGE turnover and clearance44, 269.  OST48 is expressed 
in most cells and tissues270, including macrophages48 and mononuclear cells49. In the kidney, 
previous studies have shown OST48 expression in glomerular cells including podocytes270, 271, 
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mesangial cells48 and proximal tubules270, 271, where it is postulated to mediate the uptake and 
degradation of AGEs51. The process whereby AGEs are cleared by OST48 in the kidney is not well 
understood50, but is thought to involve caveolin dependent sequestration and degradation of AGEs 
and then excretion via the urine 242. Based on previous studies, a strong link exists between 
impaired podocyte function and albuminuria, increased urinary AGE excretion and 
glomerulosclerosis136, 167, 272-275.  
 
Early damage to the glomeruli, specifically podocyte structural damage, is characteristic of DKD 
130, 276, 277. AGEs can induce podocyte cell-cycle arrest278, hypertrophy278 and apoptosis279, whilst a 
systemic reduction in AGEs has been shown to improve podocyte and kidney function4. Hence, 
increased facilitation of AGE excretion underpinned by an increase in OST48 expression could 
potentially improve podocyte health and alleviate DKD. Currently there are no reported studies 
identifying whether podocyte OST48 facilitates urinary AGE excretion and subsequently if 
targeting podocyte OST48 could influence kidney health. 
 
Here, we examined if facilitating greater AGE clearance via modestly increasing podocyte specific 
OST48 expression could attenuate the development and progression of DKD. 
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Methods 
Animal husbandry. All animal studies were performed in accordance with guidelines provided by 
the AMREP (Alfred Medical Research and Education Precinct) Animal Ethics Committee, 
University of Queensland and the National Health and Medical Research Council of Australia 
(E/1184/2012/B and MRI-UQ/TRI/256/15/KHA). Male C57BL/6J wild-type mice with a genetic 
insertion of the human gene encoding AGE-R1/OST-48 (DDOST) in the ROSA26 locus 
(ROSA26tm1(DDOST)Jfo) and were crossed with mice only expressing Cre under the control of the 
Podocin promoter (termed DDOST+/-Pod-Cre) were generated by Ozgene Australia (Ozgene, Perth, 
WA, Australia). Between 6-8 weeks of age (Week 0), experimental diabetes (DIAB) was induced in 
male wild-type (n = 9) and DDOST+/-Pod-Cre (n = 10) mice by low dose intraperitoneal injection of 
streptozotocin 257. Non-diabetic male wild-type (n = 11) and DDOST+/-Pod-Cre (n = 7) mice received 
equivalent injections of sodium citrate buffer alone. After 10 days of recovery, blood glucose 
concentrations were determined and then repeated weekly to ensure mice had diabetes ([blood 
glucose]>15mmol/L). Mice were allowed access to food and water ad libitum and were maintained 
on a 12-hour light:dark cycle at 22°C. All mice received a diet of standard mouse chow (AIN-93G) 
(Specialty Feeds, Glen Forrest, Perth, Australia). At 0 and 12 weeks of the study, mice were housed 
in metabolic cages (Iffa Credo, France) for 24 hours to determine food and water consumption and 
collect urine. Urine output was also measured during caging and urinary glucose determined by a 
glucometer (SensoCard Plus, POCD, Australia). 
 
Biochemical analyses. CML concentrations in plasma and urine were measured by an in-house 
indirect ELISA as previously described50. Urinary albumin (Bethyl Laboratories, United States) was 
normalized to the 24-hour flow rate of urine. Serum and urinary creatinine were measured 
spectrophotometrically at 505nm (Roche/Hitachi 902 Analyzer, Roche Diagnostics GmBH, 
Germany) using the Jaffe method. 
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Glomerular Filtration Rate. At 0 and 12 weeks of the study, GFR was estimated in conscious 
mice using the transcutaneous decay of retro-orbitally injected FITC-sinistrin (10mg/100g body 
weight dissolved in 0.9% NaCl), as previously described280. GFR was calculated from the rate of 
constant (α2) of the single exponential excretion phase of the curve and a semi-empirical factor. 
 
Liquid chromatography-selected reaction monitoring mass spectrometry (LC-SRM/MS-MS). 
Kidney cortices were sequentially sieved on ice to obtain fractions enriched for either glomeruli or 
tubules, which were then processed as previously described224. Peptides were desalted and analyzed 
by Information Dependent Acquisition LC-MS/MS as described225 using a Prominence nanoLC 
system (Shimadzu, Australia) and Triple TOF 5600 mass spectrometer with a Nanospray III 
interface (AB SCIEX, United States). SWATH-MS analysis was performed226 and differentially 
abundant proteins were analyzed using DAVID227. 
 
Histology and imaging. Paraffin-embedded sections were stained with either a Periodic acid Schiff 
(PAS) staining kit (Sigma-Aldrich, United States), a Trichrome (Masson) staining kit (Sigma-
Aldrich, St. Louis, Missouri, USA) or Sirius Red (Sigma-Aldrich, United States). Collagen IV was 
determined by immunohistochemistry using an anti-collagen IV antibody (1:100 dilution; ab6586; 
Abcam, United Kingdom). All sections were visualized on an Olympus Slide scanner VS120 
(Olympus, Japan) and viewed in the supplied program (OlyVIA Build 10555, Olympus, Japan). 
Slides were quantified based on threshold analysis in Fiji258. Briefly, for immunofluorescence 
staining, frozen kidney sections were stained with a combination of either anti-CML (1:200 
dilution; ab27684; Abcam, United Kingdom), OST48 (H-1; 1:100 dilution; SC-74408; Santa Cruz 
biotechnologies, United States), GRP78 (A-10; 1:50 dilution; SC-376768; Santa Cruz 
biotechnologies, United States), WT-1 (c-terminus; 1:100 dilution; PA5-16879; ThermoFisher 
Scientific, United States), synaptopodin (P-19; 1:100 dilution; SC-21537; Santa Cruz 
biotechnologies, United States), nephrin (1:100 dilution; ab27684; Abcam, United Kingdom). 
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Confocal images were visualized on an Olympus FV1200 confocal microscope (Olympus, Japan) 
and viewed in the supplied program (FV10, Olympus, Japan). For ultra-resolution 3D microscopy, 
slides were visualized on an OMX Blaze deconvolution structured illumination (SIM) super-
resolution microscope (GE Healthcare Life Science, United Kingdom). 
 
Glomerulosclerotic index (GSI). GSI as a measure of glomerular fibrosis was evaluated in a 
blinded manner by a semi-quantitative method259. Severity of glomerular damage was assessed on 
the following parameters; mesangial matrix expansion and/or hyalinosis of focal adhesions, true 
glomerular tuft occlusion, sclerosis and capillary dilation.  
 
Fixation, tissue processing and acquisition of data from electron microscopy. Renal cortex was 
processed as previously described281. Sections were cut at 60nm on a Leica UC6 ultramicrotome 
(Leica, Germany) and were imaged at 80kV on a Jeol JSM 1011 transmission electron microscope 
(Jeol, United States) equipped with an Olympus Morada (Olympus, Japan) digital camera. 
Quantification of foot process width and GBM expansion was assessed as previously described282. 
 
Statistical analyses. Results are expressed as mean ± SD (standard deviation), and assessed in 
GraphPad Prism V7.01 for Windows (GraphPad Software, United States). Normally distributed 
parameters (tested with D’Agostino & Pearson omnibus normality test) were tested for statistical 
significance by 2-way ANOVA followed by post hoc testing for multiple comparisons using the 
Bonferroni method unless otherwise specified. For comparison between groups as required, a two-
tailed unpaired Student’s t-test was used where specified. For SWATH-MS, MSstatsV3.10.0260 was 
used to detect differentially abundant proteins estimating the log-fold changes between compared 
conditions of the chosen experimental group and with the wild-type non-diabetic mice. For all 
calculations, a P < 0.05 was considered as statistically significant. 
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Data availability statement. The datasets generated and analyzed during the current study are 
available from the corresponding author upon reasonable request. 
 
Results 
Generation of a podocyte-specific OST48 knock-in mouse model. Mice were generated with a 
podocyte specific knock-in of human OST48 (DDOST+/-Pod-Cre) driven by the podocin promoter 
(Supplementary Information 1A-B) inserted at the ROSA26 locus and showed no differences in 
any anthropometric parameters or long term glycemic control (Table 1). Mice with experimentally 
induced diabetes were characterized by elevated fasting blood glucose and glycated hemoglobin 
(GHb) (Table 1). Irrespective of genotype, diabetic mice exhibited a lower body weight, renal 
hypertrophy, increased consumption of food and water and a greater urinary output when compared 
with non-diabetic mice (Table 1). 
 
DDOST+/-Pod-Cre mice had podocyte specific increases in OST48 protein content. SWATH 
proteomics measuring the relative abundancy of OST48 in renal cortices (Figure 1A) identified that 
DDOST+/-Pod-Cre mice had a subtle and significant increase in OST48 protein abundancy (2.06-
fold). Moreover, SWATH proteomics identified in fractions enriched for either glomeruli or tubular 
specific proteins (Figure 1B) subtle and significant increases in OST48 abundancy (2.59-fold and 
1.79-fold, respectively). Interestingly, it appeared that there was also a significant interactive effect 
of impaired glycemic control on the abundancy of OST48 in only the glomeruli proteins (Figure 
1B; left). Localized increases in OST48 expression in WT-1 positive cells were demonstrated in 
DDOST+/-Pod-Cre mice by confocal microscopy (Figure 1C). A podocyte-specific increase in 
OST48 expression was confirmed using ultra-resolution 3-dimensional structured illumination 
microscopy (3D-SIM) (Figure 1D). This included increased localization of OST48 to damaged 
podocyte foot processes, as indicated by nephrin loss (Figure 1D) and this was particularly evident 
in 3D reconstruction videos (Supplementary Figure 1C and Supplementary Video 1). This 
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localization of OST48 to areas of damaged foot processes was unexpected, since the current 
thinking is that an increase in OST48 could improve declining kidney function through the 
sequestering of AGEs52. These initial findings of damage to podocyte foot processes warranted 
further investigation into kidney function in DDOST+/-Pod-Cre mice and whether increased podocyte 
expression of OST48 affected glomerular filtration.  
 
Subtle increases in podocyte OST48 expression decreases GFR, exacerbating DKD. Conscious 
glomerular filtration rate (GFR) determined as a ratio of subcutaneous excretion of FITC-sinistrin, 
identified a significant decline in kidney function in DDOST+/-Pod-Cre mice (Figure 2A – 49% 
decrease, P < 0.0001). Compared to their baseline kidney function, DDOST+/-Pod-Cre mice lost 59% 
of GFR over the study period (Figure 2B). Non-diabetic DDOST+/-Pod-Cre mice also had elevated 
serum creatinine compared to their wild-type counterparts (Figure 2C – average 88% increase; P = 
0.0034), which was further increased by diabetes (Figure 2C – 58% increase; P = 0.043 for 
DDOST+/-Pod-Cre and 123% increase; P = 0.0047 for wild-type). Diabetes increased serum 
creatinine in wild type mice (Figure 2C) and decreased creatinine clearance (Figure 2D), which 
tended to further decrease in DDOST+/-Pod-Cre mice, although this did not reach statistical 
significance (Figure 2D). Compared to wild-type mice, DDOST+/-Pod-Cre mice averaged a 72% 
reduction in creatinine clearance following simultaneous blood and 24-hour urine collection 
(Figure 2E; P = 0.0052) in agreement with FITC-sinistrin based GFR assessment (Figure 2A). 
Diabetes increased 24-hour urinary albumin excretion rate, but this did not differ between wild-type 
and DDOST+/-Pod-Cre mice (Figure 2F and 2G). 
 
DDOST+/-Pod-Cre mice have damaged podocyte architecture and tubulointerstitial damage. 
Diabetes resulted in glomerulosclerosis in both genotypes (Figure 3A). In the absence of diabetes, 
DDOST+/-Pod-Cre mice also had glomerulosclerosis (Figure 3A) and greater glomerular collagen IV 
accumulation (Figure 3B) than wild-type mice which was not further elevated by diabetes. 
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Glomerular collagen IV accumulation was also present in all diabetic mice (Figure 3B). By 
electron microscopy, glomerular basement membrane thickening and podocyte foot process 
effacement were seen in DDOST+/-Pod-Cre, but not in wild-type mice (Figure 3C). In glomerular 
fractions from mouse kidney cortices, SWATH-MS proteomics identified significant increases in 
the abundance of collagen proteins (Figure 3D). Specifically, both diabetes and increased podocyte 
OST48 expression caused an increased abundance of collagen 1, collagen 6 and other structural 
collagen proteins (Figure 3D). Given that all DDOST+/-Pod-Cre mice exhibited a decline in kidney 
function, we suspected that in addition to damaged glomeruli that there would be other structural 
evidence of progressive kidney damage in the tubules of these mice. As expected, diabetes 
increased tubulointerstitial fibrosis in WT mice (Figure 4A-C). In addition, there was significant 
tubulointerstitial fibrosis in all DDOST+/-Pod-Cre mice as compared to wild-type non-diabetic mice, 
evidenced by an increase in positive connective tissue quantified from Masson’s trichrome (Figure 
4A), Sirius red (Figure 4B) and collagen IV staining in this compartment (Figure 4C). In tubule-
enriched cortical fractions, SWATH-MS proteomics identified modest increases in proteins 
associated with collagen fibril organization (CO1A1-2) (Figure 4D) in non-diabetic DDOST+/-Pod-
Cre mice as compared with WT littermates. However, with diabetes, DDOST+/-Pod-Cre mice showed 
significant accumulation of collagen IV in tubule-enriched fractions which were not seen in WT 
diabetic or non-diabetic DDOST+/-Pod-Cre mice. There were further modest increases in markers of 
tubulointerstitial fibrosis in diabetic DDOST+/-Pod-Cre but these were not different to WT mice with 
diabetes (Figure 4A-D) 
 
Tissue AGEs were localized to damaged podocytes. Podocyte AGE accumulation and OST48 
appeared to be co-localized (Figure 5A), and were prominent in areas where concomitant 
deterioration of podocyte foot processes was seen, as defined by loss of both nephrin (Figure 5A) 
and synaptopodin (Supplementary Figure 2A). 3D-SIM confirmed the appearance of 
nodules/vacuoles containing both OST48 and AGEs in DDOST+/-Pod-Cre mice in areas of podocyte 
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foot process deterioration (Figure 5B, Figure 5C and Supplementary Video 2). These changes 
were not observed in wild-type diabetic mice. Overall, there was a significant reduction in AGE 
content in kidney cortical extracts taken from DDOST+/-Pod-Cre mice (Figure 5D - genotype effect P 
< 0.05). Diabetes also increased urinary AGE excretion (P = 0.007; ~10-fold increase) when 
compared to non-diabetic mice (Figure 5E). Although not significant (P < 0.2) there was also a 
trend towards increased urinary AGE excretion in non-diabetic DDOST+/-Pod-Cre mice compared to 
wild-type non-diabetic mice. Plasma AGE concentrations at the end of the study were not different 
among groups (Supplementary Figure 2B).  
 
Podocyte OST48-mediated AGE accumulation resulted in ER stress. ER stress at sites of AGE 
accumulation within damaged podocytes was examined. DDOST+/-Pod-Cre mice exhibited an 
increase in the ER stress markers GRP-78 and spliced XBP-1 when compared to wild-type mice 
(Figure 6A). Furthermore, these ER stress markers were further increased by diabetes (Figure 6A). 
This was confirmed using glomerular enriched fractions and SWATH proteomics where diabetic 
DDOST+/-Pod-Cre mice, showed significant enrichments in proteins associated with ER stress 
(GRP75, GRP78 and TERA) compared to non-diabetic wild-type mice (Figure 6B). Antioxidant 
enzymes SOD1/SODC and SOD2/SODM were also increased by diabetes in wild-type mice 
(Figure 6B). Glomerular fractions from diabetic wild-type and DDOST+/-Pod-Cre mice were also 
significantly enriched for proteins associated with mitochondrial ATP synthesis, particularly 
biosynthesis of complex I components (NADH dehydrogenase:ubiquinone) when compared with 
non-diabetic mice (Figure 6C). 
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Discussion 
Lowering AGE burden, including facilitating renal AGE clearance has been suggested as a possible 
treatment for DKD. However, the assertion that increasing renal AGE clearance receptors, 
including OST48, may protect against DKD has not been previously investigated. Here, we have 
shown for the first time that modestly increasing OST48 in a podocyte-specific manner decreased 
glomerular filtration and caused podocyte structural damage including foot process effacement, 
leading to glomerulosclerosis and tubulointerstitial fibrosis, which were further exacerbated by 
diabetes. Surprisingly, in non-diabetic mice the decline in GFR and increased podocyte and 
glomerular damage were seen in the absence of elevations in albuminuria. Mechanistically, 
increases in OST48 in podocytes were marked by increased podocyte specific AGE uptake resulting 
in oxidative and endoplasmic reticulum stress and subsequent kidney functional and structural 
decline, where previously it has been shown that AGE uptake into cultured podocytes induces 
hypertrophy278 and apoptosis279. 
 
It was particularly interesting that albuminuria was not seen concomitantly with the loss of GFR in 
DDOST+/-Pod-Cre mice despite podocyte foot effacement, thickening of the glomerular basement 
membrane and glomerulosclerosis. Although surprising, this is consistent with clinical observations. 
For example, the prospective longitudinal Joslin Proteinuria Cohort studies283, 284 identified that the 
overall prevalence of normo-albuminuria in patients with progressive kidney disease was around 
10% and that regression from micro- and macro-albuminuria to normo-albuminuria was repeatedly 
observed. Puzzlingly, however, we observed podocyte foot effacement and glomerular basement 
membrane thickening, which are commonly attributed as causes of micro- and macro-albuminuria. 
This finding is consistent with other postulated models of the origins of albuminuria, such as the 
high glomerular sieving coefficient (GSC) hypothesis285, 286. This hypothesis suggests that 
albuminuria is driven by proximal tubule damage which prevents the reabsorption/processing of 
albumin by these cells. In support of this, tubulointerstitial fibrosis was more pronounced in 
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diabetic mice regardless of their genotype and they also had concomitant increases in urinary 
albumin excretion which not seen in non-diabetic mice. Alternatively, the absence of macro-
albuminuria seen in mice with increased podocyte expression of OST48, could also be attributed to 
the significant decline in GFR as this would limit the flux of albumin into the urine, however this 
warrants further investigation. 
 
Although we showed that increases in podocyte OST48 expression decreased renal AGE 
accumulation and increased urinary AGE excretion, this was not associated with reno-protection. In 
fact, this resulted in significant renal disease. We have shown for the first time that OST48 and 
AGEs colocalize within podocytes in areas of foot process denudation and damage. We observed 
that OST48 facilitation of podocyte AGE accumulation, resulted in a cascade of ER stress 
culminating in podocyte foot process effacement, GBM expansion, and renal functional decline. 
Increasing the urinary flux of AGEs has however been previously shown to impair renal function in 
both healthy humans4, 287 and early in the development of diabetic kidney disease in rodent 
models136, 288. 
 
Taken together, these results suggest that specifically increasing podocyte exposure and uptake of 
AGEs by facilitating their flux into the urine is sufficient to induce significant kidney damage. 
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Figures and Figure Legends 
 
Figure 1. OST48 expression and localization in the kidney. (A-B) SWATH proteomics 
quantification of total OST48 in (A) renal cortex and (B) enriched for either (left) glomeruli or 
(right) tubules in both the DDOST+/-Pod-Cre mice and the wild-type littermates. (C) Confocal 
photomicrographs of OST48 (green) and a podocyte specific marker WT-1 (red) on kidney sections 
imaged at the glomerulus. (D) 3D-SIM of podocyte foot processes stained with nephrin (red) and 
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OST48 localization (green). Scale bars from representative images for (C) confocal microscopy and 
(D) 3D-SIM were 30µm and 5µm, respectively. Results are expressed as mean ± SD with unpaired 
t-test analysis (n = 6-12) **P < 0.01, ***P < 0.001 and for proteomics (n = 4-6), MSstatsV3.10.0 
determined significant changes in the protein intensities * P < 0.05, **P < 0.01, ****P < 0.0001. 
 
 
Figure 2. DDOST+/-Pod-Cre mice exhibited a rapid and progressive decline in kidney function 
independent of macroalbuminuria. Serum and 24-hour urine was collected from mice in metabolic 
cages at week 0 and week 12 of the study. (A-C) Creatinine was measured spectrophotometrically 
at 550nm in a biochemical analyzer. (A) Serum creatinine measured at week 12 of the study. (B) 
Ratio of creatinine clearance following correction for kidney weight measured at week 12 of the 
study. (C) Change in creatinine clearance over the study, which was determined from matched 
creatinine clearance values from week 0 of the study (6-8 weeks of age) to week 12 of the study. 
(D-E) Albumin was measured spectrophotometrically at 620nm in a biochemical analyzer and the 
albumin excretion rate (AER) was determined based on the 24-hour urine flow rate. (D) AER 
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measured at week 12 of the study. (E) Change in albuminuria over the study, which was determined 
from matched albuminuria values from week 0 (6-8 weeks of age) of the study to week 12 of the 
study.  Results are expressed as mean ± SD with either two-way ANOVA or paired t-test analysis (n 
= 3-8) *P < 0.05, **P < 0.01, ***P < 0.001. 
 
 
Figure 3. Podocyte OST48 was associated with a deterioration of podocyte architecture. (A-C) 
Assessment of renal glomerular damage in the kidney with (A) Periodic-acid Schiff staining (PAS) 
and (B) collagen IV, which was then quantified based on a positive threshold protocol. DDOST+/-
Pod-Cre mice and mice with a diabetic phenotype show moderate glomerulosclerosis, indicated by an 
increase in mesangial matrix expansion (black arrow) and accumulation of the extracellular matrix 
(white arrow head). (C) Electron microscopy determined the degree of hypertrophy in the foot 
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processes (black arrow) and the expansion of the GBM (white arrow head).  Scale bars from 
representative images of (A-B) glomeruli stained with either PAS or collagen IV were 20µm. (C) 
Representative images from electron microscopy were imaged at either X3000 magnification or 
X15000 magnification were 20µm and 4µm, respectively. (D) Heat map representation of SWATH-
MS proteomics data for enzymatic pathways involved in collagen fibril organization. Significant 
proteins are represented as bolded cells, where red indicates an increase and blue indicates a 
decrease in protein concentrations. Data represented as means ± SD (n = 4-7/group). Results are 
expressed as mean ± SD with either two-way ANOVA or unpaired t-test analysis (n = 5-9) *P < 
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. For proteomics, MSstatsV3.10.0 determined 
significant (P < 0.05) log fold changes in the protein intensities between the selected experimental 
group the wild-type non-diabetic group. 
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Figure 4. Podocyte OST48 increased tubulointerstitial fibrosis. (A-C) Moreover, the presence of 
collagen in (A) Masson’s trichrome (blue staining), (B) Sirius red (red) and (C) collagen IV 
(brown), was quantified based on a positive threshold protocol. Fibrosis in the interstitium of the 
proximal tubules (black arrow) is an indicator of progressive kidney damage. The severity of these 
changes was more pronounced in the DDOST+/-Pod-Cre mice and the mice with a diabetic phenotype. 
(D) Heat map representation of SWATH-MS proteomics data for enzymatic pathways involved in 
collagen fibril organization. Significant proteins are represented as bolded cells, where red indicates 
an increase and blue indicates a decrease in protein concentrations. Data represented as means ± SD 
(n = 4-7/group).  Scale bars from representative images of (A-C) proximal tubule sections stained 
with either Masson’s trichrome, Sirius red or collagen IV were 100µm. Results are expressed as 
mean ± SD with either two-way ANOVA or unpaired t-test analysis (n = 5-9) *P < 0.05, **P < 
0.01. For proteomics, MSstatsV3.10.0 determined significant (P < 0.05) log fold changes in the 
protein intensities between the selected experimental group the wild-type non-diabetic group. 
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Figure 5. Podocyte OST48 increased AGE accumulation in podocytes. (A) Confocal 
photomicrographs of OST48 (green), CML (orange) and a podocyte foot process marker, nephrin 
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(red) on kidney sections imaged at a glomerulus. (B) 3D-SIM of podocyte foot processes staining 
for nephrin (red), OST48 (green) and CML (blue) localization. (C) 3D-SIM reconstruction of 
podocyte foot processes staining for nephrin (red), OST48 (green) and CML (blue) localization. (D-
E) CML ELISA measuring the total content of CML detected in (D) whole kidney cortex 
homogenates and in (E) 24-hour urine collections. Scale bars from representative images for (A) 
confocal microscopy and (B-C) 3D-SIM were 30µm and 5µm, respectively. Results are expressed 
as mean ± SD with either two-way ANOVA or unpaired t-test analysis (n = 5-9) *P < 0.05. 
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Figure 6. Podocyte OST48 increased ER stress markers. (A) Confocal photomicrographs of either 
ER stress marker GRP-78 (green), or XBP-1 (green) and podocyte foot process marker, 
synaptopodin (red). (B-C) Heat map representation of SWATH-MS proteomics data for enzymatic 
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pathways involved in (B) endoplasmic reticulum (ER) stress and oxidative stress (OS) enzymatic 
pathways, and (C) ubiquinone biosynthesis pathways. Significant proteins are represented as bolded 
cells, where red indicates an increase and blue indicates a decrease in protein concentrations. Data 
represented as means ± SD (n = 4-7/group). Scale bars from representative images of confocal 
microscopy were 30µm. Data represented as means ± SD (n = 5/group). For proteomics, 
MSstatsV3.10.0 determined significant (P < 0.05) log fold changes in the protein intensities 
between the selected experimental group the wild-type non-diabetic group.  
136 
 
Tables 
Table 1. Anthropometric and metabolic parameters. 
 Treatment  wild-type wild-type DDOST+/-
Pod-Cre DDOST+/-Pod-Cre  Two-way ANOVA 
 (STZ induction) non-diabetic diabetic non-diabetic diabetic G D G•D 
Body weight (g) 
12 weeks 32.82 ± 3.12 
27.14 ± 2.48 32.00 ± 4.62 
26.56 ± 4.16 
0.93 0.0001 0.59 
Kidney weight (g × body weight 103) 12 weeks 11.62 ± 1.44 14.74 ± 2.27 11.03 ± 1.21 15.93 ± 3.91 
0.74 0.0001 0.33 
Food consumption (g/24 h) 
2 weeks 3.26 ± 0.80 
3.62 ± 0.49 3.63 ± 1.12 
2.70 ± 1.01 
0.46 0.44 0.086 
 
12 weeks 2.68 ± 0.58 
4.79 ± 1.13 2.50 ± 0.95 
4.13 ± 1.55 
0.28 <0.0001 0.55 
Water consumption (ml/24 h) 
2 weeks 5.22 ± 2.91 
5.70 ± 2.91 4.74 ± 1.24 
3.24 ± 1.49 
0.12 0.58 0.29 
 
12 weeks 4.97 ± 8.49 
17.70 ± 9.77 2.94 ± 1.80 
14.06 ± 10.28 
0.35 0.0004 0.79 
Urine production (ml/24 h) 
2 weeks 0.52 ± 0.34 
1.19 ± 0.69 1.34 ± 0.83 
0.78 ± 0.91 
0.40 0.72 0.081 
 
12 weeks 1.20 ± 0.76 
15.83 ± 8.05 2.03 ± 1.77 
12.53 ± 10.84 
0.60 <0.0001 0.39 
Fasting blood glucose (mmol/L) 
12 weeks 9.22 ± 2.72 
23.53 ± 3.80 10.10 ± 2.95 
19.66 ± 6.94 
0.35 <0.0001 0.14 
GHb (mmol/mol) 
12 weeks 4.22 ± 1.68 
7.72 ± 3.79 3.35 ± 0.28 
6.86 ± 3.83 
0.45 0.0048 0.99 
Values are mean ± SD (n = 5-11), G: genotype, D: diabetes, G•D: interaction, STZ: streptozotocin, GHb: glycated hemoglobin. 
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Supplementary Figure Legends 
 
Supplementary Figure 1. Generation of a podocyte specific DDOST heterozygous knock-in 
mutant. (A) Genomic clone of DDOST bearing exon 1 used for the construction of the floxed 
targeting vector as indicated. Heterozygous mice were crossed with mice expressing podocin-Cre 
and subsequent progeny contained a ubiquitous over-expression allele. (B) Genomic Southern 
blotting confirmed the predicted DDOST allelic structures in the podocin-targeted knock-in strain. 
(C) Reconstruction of 3D-SIM of podocyte foot processes stained with nephrin (red) and OST48 
localization (green). Scale bars from representative images for 3D-SIM were 5µm. 
 
 
Supplementary Figure 2. Podocyte OST48 increased AGE accumulation in podocytes. (A) 
Confocal photomicrographs of OST48 (green), CML (orange) and a podocyte foot process marker, 
synaptopodin (red) on kidney sections imaged at a glomerulus. Scale bars from representative 
images for confocal microscopy were 30µm. (B) CML ELISA measuring the total content of CML 
detected in plasma. 
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Supplementary Video 1. Reconstruction of 7µm thick renal cortex section imaged in a 3D-SIM 
microscope. OST48 (green), nephrin (red). Scale bars from representative videos for 3D-SIM were 
5µm. Attached as supplementary video (s4238045_phd_chapter5supplementaryvideo1). 
 
Supplementary Video 2. Reconstruction of 7µm thick renal cortex section imaged in a 3D-SIM 
microscope. OST48 (green), CML(blue) and nephrin (red). Scale bars from representative videos 
for 3D-SIM were 5µm. Videos can be supplied upon request. Attached as supplementary video 
(s4238045_phd_chapter5supplementaryvideo2). 
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Chapter 6: Conclusions   
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Overview 
DKD is an important risk factor for cardiovascular disease. Understanding the development of DKD 
is crucial in reducing the morbidity and mortality associated with diabetes. AGEs have long been 
considered an important pathological factor contributing to DKD. This thesis investigates the 
currently lacking knowledge surrounding the lesser known AGE receptor OST48, its signalling 
pathways and the impact of changing its expression patterns on kidney/liver function in health and 
diabetes.  We aimed to provide key information on which further studies to develop new therapies 
or re-purposing of other compounds, could be based to enhance treatment options targeting AGEs 
in DKD. This thesis investigated the physiological role of OST48 in the metabolome and proteome 
in the kidney and liver. Key findings are outlined below; 
1. Initial findings examining protein synthesis and folding identified that two-fold over-
expression of OST48 does not impact N-glycosylation by the ER in the liver. 
2. Increased OST48 protein resulted in hepatic fibrosis in the absence of steatosis, obesity and 
reduced physical activity. Otherwise increasing OST48 activated other common pathways 
implicated in NASH disease pathogenesis. 
3. Hepatic fibrosis was further exacerbated when challenged with a “second hit” injury of a 
high AGE diet, highlighting increased OST48 as a risk factor for liver damage in situations 
where AGEs are plentiful such as in type 2 diabetes.  
4. Adding a high AGE diet, reminiscent of a western style diet, increased absorption of dietary 
AGEs by OST48 via both the gastrointestinal tract and the liver.  
5. Mechanisms driving hepatic fibrosis centred around increased hepatic ER stress and the 
preferential fuel utilisation of ketones and fatty acids. 
6. Contrary to current perceptions, over-expression of OST48 in mice did not delay the onset 
and/or progression of DKD. 
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7. Global increases in OST48 facilitated excretion of AGEs in the urine, however, this did not 
improve kidney function and/or health. 
8. Ultra-resolution microscopy of mice with selective over-expression of OST48 in podocytes 
imaged for the first time the selective binding of AGEs and OST48 within the podocyte. 
9. Knock-in of podocyte OST48 leads to a decline in kidney function and significant 
glomerular damage, which are exacerbated by diabetes. 
10. Glomerular and tubular enriched protein fractions are both affected by increases in podocyte 
OST48 expression. 
11. Overall, we identified new insights into the role the OST48 plays in kidney health as well as 
identifying a novel podocyte specific pathway relevant to diabetic kidney injury.  
 
General discussion and future directions 
We completely understand that with the advent of technologies developed in recent years (e.g. 
CRISPR/Cas9) that there are limitations surrounding the use of the Cre-LoxP technology in our 
mouse model knock-in system. However, at the time of the study design, the Cre-LoxP technology 
was the most advanced knock-in technology available for specific insertion at a defined genetic 
locus, ROSA26. All knock-out attempts for OST48 in mice were embryonically lethal. As such, a 
heterozygous knock-in design was utilised where OST48 expressing lines were chosen with modest 
over-expression (2-3 fold) and applied to better understand the physiological role of OST48 in DKD 
and liver health. Even the advent of CRISPR technology however, it would be difficult to pursue an 
OST48 knock-out model without detrimentally affecting the N-glycosylation machinery. Our mouse 
lines were chosen with subtle increases in OST48 to provide the best chance of understanding if 
changes in OST48 would be of benefit in conditions where AGEs are plentiful and pathogenic such 
as diabetes. As such we feel that with the current technologies available, that our heterozygous 
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OST48 global and podocyte-specific knock-ins are currently the best possible animal models to 
evaluate the physiological role of OST48. 
 
Another avenue we would like to further pursue is the establishment of a primary cell culture model 
of the podocyte grown from a population of diabetic patients with and without kidney disease. 
Ideally, with the primary cell culture studies we would like to establish site-specific mutagenesis of 
OST48 over-expression and knock-down. Optimally we would hope to establish this mutagenesis 
without affecting N-glycosylation pathway machinery, which would then allow us to examine the 
effects of OST48 specifically on isolated podocyte health and function. Moreover, a pilot study on a 
clinical cohort of diabetic patients with the focus on the role of OST48 in podocyte function would 
provide greater insight into the physiological role of OST48 in humans. 
 
Alternative directions that could be pursued would be to establish a liver cell specific (for example 
hepatocyte-specific or hepatic stellate cell-specific) over-expression of OST48 in a mouse model. 
This would allow us to further understand the effective role of OST48 specifically in the liver and 
how it could affect hepatic fibrosis and fuel utilisation in the liver. We are also currently completing 
studies to better understand how changes in podocyte OST48 have influenced systemic glycaemic 
control which was discovered but not followed up in this thesis. Therefore, a pancreatic specific 
over-expression of OST48 could also provide key insight into how OST48 may impact glycaemic 
control in conditions such as diabetes. 
 
Taken together, in this thesis we present evidence that there are unappreciated roles for OST48 in 
both kidney and liver health/function. Our studies indicate that efforts to increase the expression of 
OST48 to improve pathology in diabetes, and other metabolic diseases may have undesirable side-
effects leading to kidney dysfunction, liver fibrosis and glucose intolerance. 
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